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Background and Purpose 
It has been reported that poor clinical outcome in acute stroke patients is 
strongly associated with high plasma homocysteine and cysteine levels. The 
administration of cysteine increased the infarct volume after experimental 
stroke induced by pMCAO. As CBS can produce H2S using Cys and/or Hcy as 
substrates, these observations indicate that the Cys effect may be due to its 
conversion to H2S. Moreover, administration of NaHS, a donor of H2S, 
increased infarct volume after pMCAO. It is known that H2S may be produced 
by CBS and 3MST along with CAT. However, it is not known what changes 
occur in 3MST expression under ischemic conditions in the brain. As H2S is 
known to increase after stroke, we hypothesized that the expression of 3MST 
might increase if 3MST is the major source of H2S under such conditions.  
Materials and Methods 
The regional distribution of 3MST activities and the cellular localization of 
3MST were measured in normal rat brains. And the expressions of 3MST in 
the cortex, striatum and corpus callosum were investigated before and after 
pMCAO. In vitro studies were also done in primary astrocytes including OGD 
and H2S concentration determination.  
Results 
No significant differential distribution of 3MST activities in all regions 
exhibiting mean activities in the range of about 21 to 26 µmol/g tissue/h and 
3MST activities were almost completely inhibited in the presence of 2-
ketobutyric acid. And 3MST was demonstrated to localize in astrocytes as it 
colocalized with GFAP immunoreactivities. In contrast, 3MST 
immunoreactivity did not colocalize with NeuN or OX42, indicating that it was 
not expressed in neurons or microglia. At the subcellular level, 3MST 
immunoreactivity is cytoplasmic and present in both the processes and cell 
VII 
 
soma of the astrocytes. After pMCAO 3MST was significantly down-regulated 
by about 30% at 24h in striatum, and 40-50% at 72h in cortex and striatum. 
The immunostaining results are generally consistent with the Western blot 
analysis and they clearly show that 3MST immunoreactivity colocalized with 
astrocytes before and after ischemic conditions. 3MST is also downregulated 
in primary astrocytes under OGD condition and 3MST inhibitor protects 
primary astrocytes in a short time OGD.  
Discussion 
Our finding of astrocytic expression of 3MST contradicts an earlier report that 
3MST is localized to neurons in many areas of the mouse brain and spinal 
cord. It is difficult to know the cause of such discrepancy and any explanation 
can only be speculative. However, an astrocytic localization of 3MST seems 
consistent with the even and unmarkable regional variation of the in vitro 
3MST activities. Additionally we have previously reported that H2S level in 
cortical tissues was increased by 2-fold 24h after pMCAO. This increase was 
not associated with an upregulation of CBS expression. Our present 
observation that 3MST is significantly downregulated under the same 
conditions would indicate that 3MST is not likely to be responsible for the 
increased production of H2S under ischemic conditions.   
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Nowadays, stroke is the third leading cause of death after heart disease and 
cancer. Each year, around 795000 people experience a new or recurrent 
stroke. The mortality of stroke in 2007 was 135952, which means on average, 
every 4 minutes someone dies of a stroke.[1] The proportion of deaths 
caused by stroke is 10-12% in western countries, and 12% of these deaths are 
in people less than 65 years of age.[2] And 6.8 million Americans older than 
20 years have had a stroke and collectively stroke prevalence from 2007 to 
2010 is an estimated 2.8%. Additionally the silent cerebral infarction 
prevalence is ranged from 6% to 28%, which is statistically dependent on 
increasing age.[3-5] In 2010, stroke-related disability was judged to be the 
third most common cause of reduced disability-adjusted life-years.[6] And it 
is also estimated that an additional 4 million people in the United States will 
have had a stroke by 2030, a 21.9% increase in prevalence compared to that 
in 2013.[7] A review of published studies and data from clinical trials found 
that hospital admissions for hemorrhagic stroke have elevated by 18% in the 
past 10 years, probably because of increases in the number of elderly people, 
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many of whom lack adequate blood pressure control, and the increasing use 




Strokes can be classified into ischemic stroke and hemorrhagic stroke. 
Ischemic strokes are caused by interruption of the blood supply, while 
hemorrhagic strokes are due to rupture of a blood vessel or an abnormal 
vascular structure. Of all strokes, 87% are ischemic, 13% are hemorrhagic.[9] 
And some hemorrhagic stroke develop inside areas of ischemia.[10] There are 
various sub-categories in ischemic stroke according to the presumed 
mechanism of the focal brain injury and the type and localization of the 
vascular lesion. The classic categories have been defined as large-artery 
infarction, which may be extra cranial or intra cranial, embolism from 
elsewhere in the body such as heart, small-vessel disease, systemic 
hypoperfusion (general decrease in blood supply such as in shock) and other 
determined cause such as dissection, hypercoagulable states, sickle cell 
disease and infarcts of undetermined cause (two possible causes, no cause 
identified, or incomplete investigation).[10, 11] Hemorrhagic stroke is also 
classified into intra-axial hemorrhage (blood inside the brain) and extra-axial 
hemorrhage (blood inside the skull but outside the brain). Intra-axial 
hemorrhage is due to intraparenchymal hemorrhage or intraventricular 
hemorrhage (blood in the ventricular system). 8% to 12% of ischemic strokes 
and 37% to 38% of hemorrhagic strokes result in death in 30 days among 
those who are from 45 to 64 years old.[12] 
 
1.1.3. Risk Factors 
 
Risk factors are traits and lifestyle habits that increase the risk of disease. It 
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has been identified that high blood pressure, high blood cholesterol and 
other lipids, disorders of heart rhythm are among the most important 
biological risk factors for stroke. Elevated plasma levels of homocysteine, 
obesity, physical inactivity, smoking and diabetes mellitus could be minor risk 
for stroke. And risk factors can be generally classified as modifiable or fixed. 
Some modifiable risk factors are common and affect health in several ways, 
which provide opportunities to modify risk in large numbers of people. Fixed 
risk factors, such as atrial fibrillation and TIAs, are less prevalent and more 
specific than the common risk factors for stroke. Risk factors being identified 
explain only about 60% of the total attributable risk.[13, 14] So it is vitally 
necessary to identify the other 40% gap we have not investigated, some of 
which might be inherited. In a heart study, a documented parental ischemic 
stroke by the age of 65 years was associated with a 3-fold increase in ischemic 
stroke risk in offspring, even after adjustment for other known stroke risk 
factors. The absolute elevation of the increased risk was greatest in those in 
the highest quintile of the risk score. By age 65 years, people in the highest 
risk score quintile with an early parental ischemic stroke had a 25% risk of 
stroke compared with a 7.5% risk of ischemic stroke for those without such a 
history.[15] Additionally, more than 90% of ischemic heart disease is 
explained by identifiable risk factors.[13, 14] Recently some of the risk factor 
is found involving to gender difference, specifically to women. According to 
the data from Framingham Heart Study, women with natural menopause 
before 42 years of age had twice the ischemic stroke risk of women with 
natural menopause after 42 years of age.[16] And the risk of ischemic stroke 
or intracerebral hemorrhagic stroke during pregnancy and the first six weeks 
after giving birth was 2.4 times greater than for nonpregnant women of 
similar ages and races, according to the Baltimore-Washington Cooperative 
Young Stroke Study. The risk of ischemic stroke during pregnancy was not 
increased during pregnancy period but was increased 8.7 times during the 
first 6 weeks after the delivery. Intracerebral hemorrhage showed a small 
4 
 
relative risk of 2.5 during pregnancy that increased rapidly to a relative risk of 
28.3 in the first 6 weeks after the delivery. The excess risk of stroke 
attributable to the combined pregnancy/postpregnancy period was 8.1 per 




About 25% stroke patients are dead by a month, about 30% by 6 months, and 
50% by 1 year.[18, 19] The mortality after one month is nearly 50% for those 
who possess intracerebral and subarachnoid hemorrhage, which is 
significantly higher than those who do not. In a short time, mostly the cause 
of early mortality is neurological deterioration with contributions from other 
causes such as infections secondary to aspiration, but later deaths are more 
commonly caused by cardiac diseases or complications of stroke.[19] In the 
Oxfordshire community stroke project classification, mortality after one year 
for people with total anterior circulation syndromes (around 60%) is 
considerably higher than that for those with partial anterior circulation and 
posterior circulation syndromes (around 15-20%), which in turn is higher than 
that for stroke patients with lacunar syndromes (10%).[20] The best 
predictors of stroke recovery after three months are the initial neurological 
deficit and age; other factors include high blood glucose concentrations, body 
temperature, and previous stroke.[21] A third of patients with primary 
intracerebral hemorrhage have a rapid expansion of the hematoma within 
the first few hours after presentation, which is an independent predictor of 
poor outcome after three months beside other factors such as age and initial 
neurological deficit.[22]  
 
Post transient ischemic attack or minor stroke, the risk of further stroke is 
remarkably higher than previously expected, approaching as high as a third in 
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the first month in some subgroups.[23-26] Patients at very high risk of 
recurrence within seven days can be identified based on their age, blood 
pressure, and the characteristics and duration of their symptoms; simple 
scores have been developed, on the basis of these factors, to predict those 
patients at greatest risk who might benefit most from early risk-factor 
modification.[27, 28] Additionally, imaging strategies can identify patients at 
increased risk of recurrence. For instance the presence of diffusion-weighted 
image lesions on magnetic resonance scanning or of occluded vessels on 




1.1.5.1. Ischemic Stroke 
 
An ideal therapy for ischemic stroke is either removing the blockage by 
breaking the clot down (thrombolysis), or removing it mechanically 
(thrombectomy). The more rapidly blood flow is restored to the brain, the 




Thrombolysis with recombinant tissue plasminogen activator (tPA) is the most 
biologically effective treatments for acute ischemic stroke in the market so far. 
It improves the rate of independence and late mortality in long term 
treatments. However it is detrimental to human being in short period 
therapies. tPA increases the risk of death in the short term if given before 
three hours of symptom onset while the increase in long term mortality is not 
significant.[31] And the increase or decrease is not associated with the age of 
the patients.[31] The prevention of disability is around 0.6% in ischemic 
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stroke patients.[32] Moreover, tPA does not improve mortality although it is 
very effective in disability reduction.[33] However only around 5% of stroke 
patients are treated by tPA in the most stroke centers.[34] In some developed 
countries, tPA or some other thrombolysis are not of the standard treatments 
in case of stroke in most of the hospitals. Partly the reason is that objective 
evidence regarding the efficacy, safety, and applicability of tPA for acute 
ischemic stroke is insufficient to warrant its classification as standard of 
care.[35] And it might also be a reason that very few physicians in the 
hospitals are familiar to acute stroke management. In some countries, such as 
the US, reimbursement from issuance firms might also be a problem.  
 
One of the major side effects of thrombolysis is symptomatic intracerebral 
hemorrhage which is around 6% out of all of the cases. But this value was 
somehow lower in European countries, although the definition of 
symptomatic hemorrhage is slightly different from that in the original 
trials.[36] Risk of symptomatic intracerebral hemorrhage increases with age, 
high blood pressure, hyperglycemia, severe neurological deficits and probably 
the early ischemic changes on CT.[37, 38] Most of the existing publications 
supporting the increase risk of hemorrhage with early ischemic change on CT 
are based on trials of therapy initiated up to 6h after the symptom, in that 
case they may not be relevant to short time therapies initiated in a three-
hour time point.[39] However, there is still not a reproducible way to 
determine the possibility of having an intracranial hemorrhage post 
treatment.[40] One of the phase III trials suggested that prourokinase given 
intraarterially in six hours of symptom onset is capable of rendering better 
outcomes. And intravenously administered tPA is widely used in various 
hospitals with outcomes similar to those from preclinical and clinical trials 
although it is not yet approved by the US Food and Drug Administration 
(FDA).[41, 42] Also the efficacy is largely doubted with respect to 
noninterventional therapy in ischemic stroke in the three to five hours of 
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It is shown that the administration of oral aspirin within 48 hours of symptom 
onset of ischemic stroke reduces morbidity on 14-day time window and 
mortality although the benefit is quite limited, with only about 0.9% patients 
saved from death or disability. And prevention of death or disability is only 
around 0.4% out of all ischemic stroke patients.[32, 44, 45] The main reasons 
of choosing aspirin as a treatment are low cost, administration ease and low 




Thrombectomy is to mechanically remove the clot occurring in a large blood 
vessel and may be an option for those who are not eligible or do not show 
any improve with intravenous thrombolytics, although the procedure has not 
been thoroughly investigated in randomized control trials.[46, 47]  
 
1.1.5.2. Hemorrhagic Stroke 
 
Hemorrhagic stroke is a devastating problem. Mostly it is caused 
spontaneously as intracerebral hemorrhage related to hypertension. 
Currently the role of surgery has been proved more capable of preventing 
rebleeding from lesional problems, although some controversy for routine 
treatment of spontaneous intracerebral hemorrhage still exists. Patients with 
up to 3 cm cerebellar hemorrhages or with imminent deterioration from 
superficial lobar hemorrhages may benefit more from the surgery.[48, 49] 
Additionally, the trials on some alternate surgical approaches to intracerebral 
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hemorrhage are needed. So in this case practitioners or clinicians should 
consult published guidelines for recommended treatments and consider each 




1.1.6.1. Primary Prevention 
 
The dramatic reduction on mortality from stroke is largely attributable to 
thoroughly studied risk factors.[50] Meanwhile hypotensive drugs, which are 
more effective than the previous ones, have been widely used in western 
societies from the 1950s.[51] It is also influenced by the modification of other 
risk factors such as socioeconomic status, cholesterol, diabetes, atrial 
fibrillation, and reduction in smoking rates.[52, 53] The evidence for the 
treatment of hypertension in patients without previous stroke or transient 
ischemic attack suggests the utility of warfarin for patients with atrial 
fibrillation, lipid reduction with statins in patients with pre-existing ischemic 
heart disease, and utility of aspirin in women older than 45 years.[54-58] And 
also stroke prevention strategies are largely short in developing countries 
accounting for around 70% of nearly five million stroke-caused deaths per 
year.[59] 
 
1.1.6.2. Secondary Prevention 
 
Secondary prevention has been proved more effective than primary 
prevention and it has been one of the major therapies in stroke management 
since past several decades.[60] Initially there was no proven secondary 
prevention strategy for stroke until aspirin was firstly introduced in 1978.[61] 
And ten years later aspirin plus dipyridamole was utilized in hospital.[62] In 
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1991 carotid endarterectomy was used on patients with symptomatic carotid-
artery stenosis and two years later warfarin was applied on patients with 
atrial fibrillation.[63, 64] Clopidogrel was induced in patients at risk of 
ischemic events in 1996.[65] The strategies of blood pressure reduction with 
perindopril and indapamide or ramipril were proposed in 2001 and 
methodology of cholesterol reduction with atorvastatin was suggested in 
2006.[66-68] Additionally, a tremendous array of secondary prevention 
strategies is available now, with most patients qualifying for one or up to 
three or more interventions at hospital discharge. 
 
1.1.7. Experimental Models 
 
It has been investigated by plenty of studies in which many experimental 
models were used to study cerebral ischemia in terms of both in vivo and in 
vitro. In vivo animal models have been conducted on mainly mammals such 
as rodents, gerbils, canines and primates. In vitro primary culture, cell lines 
and tissue culture are also widely used in ischemia or hypoxia study at a 
cellular level.  
 
1.1.7.1. In Vivo Models 
 
A considerably big database for animal experimental models makes a 
screening or a selection for an appropriate model applicable to study the 
pathophysiology and therapy of brain ischemia. A wrong or an inappropriate 
choice without proper knowledge of the individual pathophysiology may 
result in a false conclusions. And moreover another crucial consideration is 
also involved to the control of physiological variables such as body 
temperature, blood pressure, blood gases or glucose levels, which might be 
confounders compromising the validity of the data. In that case animal 
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models should be carefully selected according to the following criteria to 
minimize the misconceptions and bias of the experiments.[69]  
 
 The surgery that causes the cerebral ischemia should be highly 
reproducible.  
 Monitoring and maintenance of physiological stability should be easily 
applicable.  
 The cost associated with the induction of the ischemia and 
measurement of physiological outcome should be reasonable and 
valuable.  
 Biological endpoints should be defined and accurately measured.  
 The experimental model should be chosen in accordance with the 
process and physiologic responses in the clinical condition.  
 It should be destitute of certain level of side effects.  
 
Generally speaking, global ischemia models in terms of either complete or 
incomplete are much easier to perform compared to focal ones. However, 
they are also more unconnected to real clinical conditions after ischemia than 
the focal stroke models, because global ischemia is not stimulated as a 




The mostly used global ischemia is two-vessel occlusion model, which is 
classified as a forebrain ischemia or cerebral ischemia model due to its 
harmlessness to the midbrain and the cerebellum. It was first developed in 
1984 and during the ischemic period mean arterial blood pressure is reduced 
to 50 mmHg by drawing blood from either the jugular vein or femoral artery, 
which is instantly followed by occlusion of bilateral common carotid arteries 
to induce brain insults to a certain level that causes neuronal damage.[70] 
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The withdrawn blood is injected back to the animal at the end of the whole 
surgery. The model produces a rectangle wave ischemia in which the 
transition from healthy tissue to ischemic insults with an angular subsequent 
reversal.[71, 72] This model results in delayed neuronal injury in particular in 
susceptible brain regions, including the CA1 pyramidal neurons of the 
hippocampus, the dorsoventral striatum, and neocortex with survival 
duration longer than 20-30 min.  
 
The advantages of model are as follow: 
 Easily conducted 
 Highly reproducible 
 High animal survival rate which is nearly 90% 
 Easy to monitor the physiological and molecular changes after the 
induced ischemia  
The disadvantages of the model are as follow: 
 A general anesthesia is necessary 




Focal cerebral ischemia happens when blood flow in one or multiple specific 
brain regions is remarkably limited, which is usually caused by the occlusion 
of a major cerebral artery, such as the middle cerebral artery. Multifocal 
ischemia has been described as spotty reduction of cerebral blood flow, 
which can be resulted by injection of embolus material into a brain artery.[73] 
The causation of ischemia can be classified as extravascular or 
intravascular.[74] Extravascular mechanisms are blood flow obstacles in terms 
of ligation, clipping or electrocauterization. And intravascular mechanism is 
based on an intravascular occlusion with respect to suture in focal cerebral 
ischemia or injection of blood clots and other embolus material in multifocal 
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cerebral ischemia models. 
 
1.1.7.1.2.1. Permanent Transcranial Model 
 
The permanent transcranial model requires craniotomy and incision of the 
dura before the proximal middle cerebral artery can be identified. And 
generally it is also necessary to remove the coronoid process of the mandible 
and zygoma and open a small window lateral to the foramen ovale.[75] And 
tandem occlusion of the distal middle cerebral and ipsilateral common carotid 
arteries is applied to cause reproducible infarctions.[76] The limitations of the 
permanent transcranial model include technical intricacy, spontaneous 
impairment of cerebral blood flow regulation by the injuries of autonomic 
nerves, and also craniotomy. And it has been shown in post-surgical period to 
alter brain temperature, intracranial pressure, and blood-brain barrier 
penetrability.[77-83]   
 
The advantages of model are as follow: 
 Similarity of the intracranial circulation to that of humans 
 Abundant neurochemical and genetics data 
 Low cost 
 
The disadvantages of the model are as follow: 
 Highly invasive 
 Technically demanding 
 High mortality  
 Poor feeding due to the destruction of muscles and joint needed for 
chewing. 
 




The filament model effectively blocks blood flow into the MCA by insertion of 
a suture at the origin of the MCA. Specifically, a piece of surgical filament is 
introduced into the internal carotid artery and pushed forward till the tip of 
the suture occludes the origin of the middle cerebral artery, leading to an 
interruption of blood flow and subsequent brain ischemia in its area of supply. 
And the reperfusion is achieved by the removal of the suture after a certain 
interval or period to induce a transient MCAO. On the other hand, permanent 
MCAO is induced if the filament is kept in place where it is pushed to. But the 
filament is later modified as introduction by the external carotid artery, which 
allows closure of the access point with preserved blood supply via the 
common and internal carotid artery to the brain after the removal of the 
filament.[84-91]  
 
The advantages of model are as follow: 
 Compatibility with transgenic or knock-out animals  
 Reproducibility in ischemic injury 
 Easy surgical procedures 
 Low costs 
 
The disadvantages of the model are as follow: 
 Inconsistence of infarct volume 
 Insufficient occlusion 
 Subarachnoid hemorrhage 
 Hyperthermia 
 Necrosis of the ipsilateral extracranial tissue  
 Inapplicability on some rat strains 
 
1.1.7.1.2.3. Thromboembolic Model 
 
Thromboembolic models of focal cerebral ischemia were firstly introduced in 
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dogs and have subsequently been adapted to mice and rats.[92-94] 
Nowadays thromboembolic models are gradually used to mimic human 
thromboembolic stroke, especially for the investigation into thrombolytic 
therapies for acute focal cerebral ischemia. As tPA is the only drug that has 
been approved by FDA as a treatment for curing human acute ischemic stroke, 
thrombolysis with tPA is an effective therapy for acute thromboembolic 
stroke.[95-97] However, hemorrhagic transformation, neurotoxicity and short 
treatment time probably limit the model for widespread implementation of 
tPA stroke therapy. So for the model is it essential to identify new strategies 
to increase thrombolytic efficacy and suppress tPA associated neurotoxicity 
and hemorrhagic transformation.  
 
The advantages of model are as follow: 
 Pathophysiological relevance 
 Suitable to investigate thrombolytic treatment such as tPA or recovery 
after reperfusion 
 
The disadvantages of the model are as follow: 
 Low variability and excessive failure caused by spontaneous 
recanalization 
 Mortality rates are high 
 Just fit some specific experiments and hypotheses  
 The reproducibility of this model is largely dependent on the 
experience of the operator and surgical nuances in each individual 
laboratory.  
 
1.1.7.2. In Vitro Models 
 
In vitro models have been induced to neuroscience research increasingly in 
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these years to better investigate the molecular pathways of brain ischemia. In 
these models, primary neuronal cultures, organotypic cultures and acute 
brain tissue slices are widely incubated in oxygen glucose deprivation (OGD) 
medium to stimulate the interruption of the supply of oxygen and glucose to 
the brain tissue.[98-104] Firstly the cultures or slices are incubated in medium 
with glucose and in atmosphere environment with oxygen, which is followed 
by the induction of OGD or hypoxia condition. And additionally there is 
generally a normoxia condition again after in vitro ischemia to mimic the in 
vivo blood flow reperfusion period. Recently some other methods such as 
glutamate receptor mediated excitotoxicity and chemical ischemia are also 
utilized to imitate in vivo ischemic conditions.[105-107] 
 
1.1.7.2.1. Oxygen Glucose Deprivation 
 
The most widely used method to induce ischemic conditions is oxygen 
glucose deprivation, which can be achieved by many methods, including the 
use of anoxic chambers or immersion in glucose free medium bubbled with 
pure nitrogen to expel dissolved oxygen.[101, 102, 108-110] The OGD results 
have been proved of consistence and reproducibility compared to direct 
neuronal exposure to glutamate agonists to elicit excitotoxicity, suggesting 
that this approach can simulate the in vivo situation in a better way. 
 
In organotypic hippocampal slices in OGD condition, dentate gyrus granule 
cells are the most resistant, whereas pyramidal cells are the most vulnerable. 
The high defenselessness of pyramidal cells to OGD combined with the high 
resistance of dentate gyrus granule cells to OGD dramatically reproduces the 
selective vulnerability to induction of ischemia in vivo.[111] In rodent models 
of ischemia selective neuronal death can be easily induced in the CA1 region, 
which generates over the two to four days post-surgery, known as delayed 
neuronal cell death.[111] In organotypic hippocampal slice cultures, OGD 
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induces neuronal death within 1 day in the CA1 region, and the insult extends 




Homocysteine (Hcy) is a relatively simple sulfur-containing amino acid with 
the molecular formula HSCH2CH2CH(NH2)COOH. And it is also a homologue to 
cysteine, from which it only differs for the presence of an adjunctive 
methylene group (-CH2-). Hcy is not a traditional nutrient as some other 
amino acids as it needs to be endogenously synthesized from the precursor 
methionine through a multiple step procedure by which basically the terminal 
Cε methyl group is removed from methionine (Figure 1-1). Then the 
compound is reconverted to methionine by methionine synthase or betaine 
homocysteine methyltransferase, or alternatively converted into cysteine 
catalyzed by cystathionine β-synthase (CBS) or 3-mercaptopyruvate 
sulfurtransferase (3MST) in combination with cysteine aminotransferase (CAT). 
In the process of the metabolic cycle of Hcy, the presence of vitamins, such as 
vitamin B9 (well known as folic acid or folate), vitamin B6 (also known as 
pyridoxine) and vitamin B12 (common known as cobalamin) is crucial, in that 
case the deficiency of one or more of these vitamins is involved to various 
kinds of hyperhomocysteinemia.[113] Other vital determinants of plasma Hcy 
concentration are genetic polymorphisms, especially those associated to the 
enzyme methylenetetrahydrofolate reductase (MTHFR), methionine synthase, 
methionine synthase reductase, and cystathionine β-synthase, and recently 





Figure 1-1 Homocysteine metabolism  
Hcy is reconverted to methionine by methionine synthase or betaine 
homocysteine methyltransferase, or alternatively converted into cysteine 
catalyzed by cystathionine β-synthase (CBS) 
This figure is obtained from Lippi (2012) [116] 
 
The investigation between elevated homocysteine level and many human 
diseases has been started since the 1960s, when the patients of 
homocystinuria were discovered involved to vascular disorders. And later Hcy 
was found associated with the pathogenesis of vascular disease by a direct 
effect of the amino acid on arterial cells and tissues via the analysis of former 
cases of homocystinuria in 1933 and cobalamin C disease in 1968.[113] These 
earlier investigations have facilitated plenty of cross-sectional and prospective 
studies over the latter decades, trying to figure out whether Hcy could be the 
real key culprit or accomplice in cardiovascular or cerebral diseases. And 
there are also different kinds of Hcy caused thrombosis which can be 
classified into venous thrombosis, arterial thrombosis and lymphatic 
thrombosis, which are characterized by distinct specific pathogenesis, 
18 
 




Although some disease such as periodontal disease may henceforth be 
considered a risk factor for arterial thrombosis, it does not spontaneously 
translate into a risk factor for venous thrombosis and vice versa.[121-123] 
One well-established exception is probably Hcy. Nowadays enough attention 
has been paid on the association between hyperhomocysteinemia and both 
venous and arterial thrombosis. Additionally it is also noticed that Hcy is not 
just involved to the pathogenesis of traditional thrombotic disorder, but also 
to that of other non-thrombotic disorders including pregnancy complications, 
bone loss, decreased bone strength and increased risk of fracture.[124, 125] 
Moreover elevated blood serum homocysteine is a risk factor for 
cardiovascular disease as well. And nevertheless it is also found that high 
level of Hcy is strongly associated with many neurodegenerative diseases, 
such as Alzheimer’s disease, vascular dementia, cognitive impairment and 
stroke.[126, 127] 
 
1.2.1.1. Cardiovascular Disease 
 
It has been indicated that elevated plasma levels of homocysteine are 
associated with an increased risk of cardiovascular ischemic events. Several 
pathophysiologic mechanisms and epidemiological studies by which elevated 
homocysteine level is proved as a risk factor of cardiovascular disease have 
been proposed.  
 




Hyperhomocysteinemia is found playing a pathogenic role in cardiovascular 
disease with respect to homocystinuria, higher risk of premature, frequently 
fatal, thromboembolic events and autopsy evidence.[128] And the conclusion 
is also confirmed by clinical and epidemiologic studies, implying a role for 
homocysteine in atherosclerotic cardiovascular disease, although the results 
remain contradictory.[129-131] Several mechanisms have been proposed to 
explain the link between hyperhomocysteinemia and cardiovascular disease, 
including reactive oxygen species generation, coagulation cascade activation, 
endothelial dysfunction, production of inflammatory mediators.[132] It has 
been suggested that homocysteine can affect hemostasis leading to a 
prothrombotic state, activate platelets and promote expression of the 
CD40/CD40L from activated platelets.[133, 134] It has also been shown by 
studies on animals that moderate hyperhomocysteinemia leads to 
accelerated development of atherosclerosis.[135, 136] And the atherogenetic 
influence of hyperhomocysteinemia remarkably varies on diet, sex, severity 
and duration of hyperhomocysteinemia. It is also shown that ApoE-deficient 
mice exhibit accelerated arterial thrombosis and endothelial dysfunction 
when fed with hyperhomocysteinemic diet.[137] Cell culture studies 
demonstrate that homocysteine promotes vascular smooth muscle cell 
growth, adhesion of leukocyte to endothelial cells and inflammation by 
increasing production of several proinflammatory mediators.[138, 139] 
Although, there is still no effect on platelet activation despite results suggest 
that the mechanism of accelerated thrombosis may be associated with 
diminished production of endothelium derived nitric oxide or other 
prothrombotic factors, there are still strong evidence that impairment of 
vasodilatation is mediated by endothelium derived nitric oxide, and that 
hyperhomocysteinemia leads to a dose dependent increase of intracellular 
ROS generation and to a decrease of endothelial NO release in different 
experimental settings.[140-144] Additionally, another potential mechanism 
for endothelial dysfunction during hyperhomocysteinemia is inhibition of 
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oxide nitric production caused by asymmetric dimethylarginine which is an 
endogenous eNOS inhibitor, increasing dramatically after acute methionine 
loading and elevation of plasma level correlating with impairment of 
endothelium dependent relaxation in human subjects.[145] The increase of 
asymmetric dimethylarginine in hyperhomocysteinemia is caused by 
decreased catabolism by dimethylarginine dimethylaminohydrolase which is 
an enzyme that functions hydrolyzation, providing a potential link between 
hyperhomocysteinemia and the increase in asymmetric dimethylarginine.[146]  
 
1.2.1.1.2. Epidemiological Studies 
 
The analysis that links venous thrombosis to hyperhomocysteinemia was 
from 24 retrospective studies and 3 prospective studies, showing that a 5 
μmol/L elevation on Hcy concentration was associated with a 60% (95% CI 
10%-134%) higher risk in retrospective studies and a 27% (95% CI 1%-59%) 
higher risk of venous thrombosis in prospective studies.[127] And the 
relationship between hyperhomocysteinemia and coronary heart disease has 
been eventually conducted from 26 prospective cohort studies measuring Hcy 
concentration and incidence of disease in the general adult population, 
indicating 20%-50% increased risk of coronary heart disease for each 5 
μmol/L higher on Hcy concentration. The combined risk ratio for coronary 
events of 1.18 (95% CI 1.10-1.26) for each increase of 5 μmol/L in Hcy level, 
independently of traditional cardiovascular risk factors.[147] Similarly the 
relationship between hyperhomocysteinemia and peripheral arterial disease 
is analyzed from 14 observational studies that measured Hcy levels in patients 
with peripheral arterial disease, showing that Hcy was significantly increased 
by 4.31 μmol/L (95% CI 1.71-6.31 μmol/L) in patients as compared with 
controls.[148] Finally, an analysis consisting of 10 case-control studies 
including 614 patients and 762 controls shows that serum Hcy levels in 
patients is associated with retinal vascular occlusive disease. Patients with all 
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types of retinal vein occlusion possess 0.867 μmol/L higher plasma Hcy levels 
than controls (95% CI 0.735-0.999 μmol/L). The concentration of Hcy was also 
1.174 μmol/L higher in patients with retinal artery occlusion compared to 
that of controls (95% CI 0.947-1.402 μmol/L).[149] 
 
1.2.1.2. Neurodegenerative Disease 
 
Studies illustrate the link between elevated concentration of homocysteine 
and occurrence of Alzheimer's disease, stroke and other human 
neurodegenerative pathologies besides cognitive impairments.  
 
1.2.1.2.1. Alzheimer’s Disease 
  
Hyperhomocysteinemia has been proposed to be a modifiable risk factor for 
Alzheimer's disease.[150] Most of the direct evidence on the association 
between hyperhomocysteinemia and Alzheimer's disease comes from human 
studies. It was firstly reported in 1990 that elevated Hcy concentration was 
observed in 22 primary degenerative dementia patients.[151] After that many 
retrospective studies emphasize on the comparison between plasma Hcy 
levels in Alzheimer's disease patients and their age matched healthy controls 
to establish a potential connection. Plasma Hcy levels varied from 11.5 μM to 
16.4 μM in control groups while levels ranged from 16.3 μM to 23.52 μM in 
Alzheimer's disease patients.[152-161] Also lots of prospective studies start 
with a group of healthy subjects and follows them for a certain period ranging 
from several months to 35 years, when the incidence of Alzheimer's disease is 
recorded and the risk ratio is calculated. The Hcy baseline from the subgroup 
of patients who develop Alzheimer's disease and the rest of the original 
group are compared when the studies end. In all of the investigations it is 
found that hyperhomocysteinemia is probably a risk factor for Alzheimer's 
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disease or cognitive decline.[162-171] Some prospective studies on the 
disease development in mild cognitive impairment and Alzheimer's disease 
claim that hyperhomocysteinemia predicts both the conversion of mild 
cognitive impairment to Alzheimer's disease and further cognitive decline, 
whereas the majority of these prospective studies support the hypothesis 
that hyperhomocysteinemia is the essential sticking point by revealing the 
chronological order that hyperhomocysteinemia happens before the 
cognitive decline or Alzheimer's disease in the old people. Despite the strong 
support offered by observational studies, the cause-effect relationship 
between hyperhomocysteinemia and Alzheimer's disease is also established 
via obtaining evidence from interventional studies, such as randomized 
controlled trial which is considered to be the best standard to test the efficacy 
of any treatment. In one of the studies Hcy inhibiting treatment improves the 
beneficial effect of cholinesterase inhibitors in Alzheimer's disease 
patients.[172] But in the contrary, an intervention for patients with mild to 
moderate Alzheimer's disease followed for three years found that Hcy 
reducing treatment, which is achieved due to high dose supplementation 




Elevated plasma Hcy is found associated with an increased risk of stroke.[174-
176] It was first noticed in 1997 that plasma Hcy concentration above 20 μM 
are associated with a nine times increase of the myocardial infarction and 
stroke risk, compared to the concentrations below 9 μM.[177] And It was 
then found in 2002 that every increase of 2.5 μM in plasma Hcy may be 
associated with an increase of stroke risk by one fifth.[178] Moreover, an 
association was also brought up by analyzing the occurrence of ischemic 
stroke in the population of Northern Poland with regard to risk factors of the 
disease in 2008.[174] So in that case it is hypothesized that 
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hyperhomocysteinemia might be a risk factor of ischemic stroke, which is 
independent of other conventional risk factors of this disease, although there 
are many different opinions on the biotoxicity of Hcy on the hemostasis 
process. The relationship between Hcy levels and stroke was evaluated from 
prospective or retrospective studies involving a total of 1113 stroke events 
were included in a meta-analysis of individual participant data. After 
adjustment for cardiovascular risk factors and regression dilution bias in 
prospective studies, 25% lower than usual Hcy level which is around 3 μmol/L 
was associated with a 19% (odds ratio 0.81; 95% CI 0.69-0.95) lower risk of 
stroke.[131] The risk of stroke was also found associated with the genetics of 
hyperhomocysteinemia, T allele of the methylenetetrahydrofolate reductase 
(MTHFR EC, 1.5.1.20) C677T polymorphism.[179] In genetic and 
environmental studies, increased serum homocysteine has been implicated as 
a modifiable determinant of cerebrovascular events.[180] In a cohort study it 
is found that deficiencies in folate, B12 and pyridoxine result in the majority 
of elevated homocysteine levels in the study cohort. Additionally, It has been 
suggested that increased dietary and supplemental intake of vitamin B6 may 
decrease stroke risk.[181] However, the large prospective Vitamin in Stroke 
Protection trial did not show any benefits with treatment with B6, B12 or 




The cause of pathological hyperhomocysteinemia was first described in 1962 
in a cohort of patients with mental retardation.[183] Homocystinuria is 
indicated as a result of impairment of the methionine synthesis pathway. 
Major clinical manifestations influence the central nervous, vascular and 
skeletal systems. Sequence variations in the CBS gene (CBS; EC, 4.2.1.22) 
defect leading to CBS protein deficiency were the first reported as being 
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involved to homocystinuria.[184, 185] Then later, non-synonymous variant 
alleles are identified in the CBS and cystathionase (CTH; EC, 4.4.1.1) genes in 
patients with high plasma level of Hcy. Homozygotes for the c.1352G>T 
variant allele (rs1021737) in the CTH gene encoding a p.S403I amino-acid 
change have dramatically higher plasma Hcy levels than other genotypes in a 
cohort of 496 Caucasian individuals.[186] And an allelic variation in the CBS 
gene, encoding a p.G307S amino-acid change, has been identified as well in 
patients of Celtic ancestry with homocystinuria.[187, 188] Another protein 
variant, p.I278T (rs5742905, c.833T>C), has also been identified in Celtic 
homocystinuria patients, whereas Heterozygotes for p.I278T are indicated to 
retain some degree of pyridoxine responsiveness to homocystinuria.[187, 189] 
Even assuming the key role both have in the synthesis of cystathione from 
homocysteine, the increased homocysteine phenotype in individuals with 
impaired CBS or CTH is not unexpected. Also 5-Methyltetrahydrofolate-
homocysteine methyltransferase (MTR; EC, 2.1.1.13) was detected taking the 
lead for the final step in the methionine biosynthetic pathway. Mutations in 
the MTR gene result in methylcobalamin deficiency G (cblG) disorder, which 
increases homocysteine, depletes methionine levels. And the mutation is 
characterized by homocystinuria.[190, 191] A common non-synonymous 
variant (p.P1173L) has been probed in more than two third of cblG 
patients.[192] In addition, 13 novel mutations, including 5 deletions and 2 
nonsense mutations were identified, leading to the synthesis of truncated 
proteins that lacked portions critical for enzyme function. The functional MTR 
is adjusted and regenerated by 5-Methyltetrahydrofolate-homocysteine 
methyltransferase reductase (MTRR; EC, 1.16.1.8) assuming that MTR is the 
final step in the biosynthesis of methionine. MTRR functionality is a crucial 
element of intracellular homocysteine levels. It has also been observed that 
patients carrying functional mutations in the MTRR gene have the 
manifestation of CblE type of homocystinuria which is a rare autosomal-
recessive disorder manifesting as megaloblastic anemia.[193, 194] An analysis 
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among Pakistan population found that elevated homocysteine level (>15 
µmol/L) is highly associated with gene polymorphism especially MTHFR 
C677T transition, folate and vitamin B12 deficiencies while gender difference 




Before the therapy of hyperhomocysteinemia a clearer evidence of causation 
is need with respect to whether Hcy is effectively a real cause of many human 
pathologies, an indirect marker or both, despite the outcomes of many 
studies seem to be capable of linking Hcy in human diseases, especially in 
cardiovascular or neurodegenerative disorders. Otherwise the lack of a causal 
relationship between hyperhomocysteinemia and diseases would make the 
basic requirements for a justifying a population screening and aggressive 
lowering therapy rash. 
 
A comprehensive search of randomized controlled trials with a follow-up 
period of one year or longer was done to establish whether Hcy suppressing 
therapy in patients with and without pre-existing cardiovascular disease is 
effective for preventing cardiovascular events and death. In the study patients 
at risk of or with established cardiovascular disease were given vitamin B6, B9 
or B12 (alone or in combination).[196] Couple of randomized clinical trials 
including more than 20 thousand participants were analyzed, obtaining a RR 
of 1.03 (95% CI 0.94-1.13) for non-fatal or fatal myocardial infarction, 0.89 (95% 
CI 0.73-1.08) for stroke, and 1.00 (95% CI 0.92-1.09) for death by any cause. In 
that case it is concluded that there is no sufficient evidence to support the 
use of Hcy reduction treatment for preventing cardiovascular or 
cerebrovascular events. Similarly it has been reported in an analysis of 
vascular disease prevention including nearly 40 thousand patients.  Allocation 
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to B vitamins had no beneficial effects on any cardiovascular or 
cerebrovascular diseases either, with hazard ratios (HR) of 1.01 (95% CI 0.96-
1.07) for coronary heart disease, 0.96 (95% CI 0.87-1.07) for stroke, 1.08 (95% 
CI 0.99-1.17) for cancer, and 1.02 (95% CI 0.97-1.07) for death from any cause. 
In sum it seems responsible to conclude that lowering Hcy level may not 
considerably relieve cardiovascular or cerebrovascular diseases, although 
identification of hyperhomocysteinemia might be somehow useful.[197] In an 
investigation showing effect of Hcy lowering by supplementation of B 
vitamins on the risk reduction of venous thromboembolism, the rate of 
recurrent venous thrombosis was significantly instinct between patients 
treated with vitamins and those with placebo. The relative HR associated with 
vitamin treatment was 0.84 (95% CI 0.56-1.26), indicating that Hcy lowering 
therapy does not help the prevention of venous thrombosis.[198] In another 
study, 17 trials involving 39,107 patients with cardiovascular and 
cerebrovascular disease were included, but no any significant difference 
between the intervention group and the control population was shown. The 
RR for patients treated with folic acid or B vitamins supplementation 
compared with controls being 1.01 (95% CI 0.97-1.05) for overall 
cardiovascular events, 1.01 (95% CI 0.94-1.07) for coronary heart disease, and 
0.94 (95% CI 0.85-1.04) for stroke. Considering neurodegenerative disorders, 
Hcy is indeed a surrogate marker for B vitamin deficiency and a neurotoxic 
agent, in that case the attention of suppressing Hcy with B supplementation 
would be undoubtedly appealing.[127] Similarly in patients with mild to 
moderate Alzheimer’s dementia, it is found that 26-week multivitamin 
supplement containing vitamins B6, B12 and folic acid was effective to 
decrease Hcy concentrations but no significant differences in cognition or 
performance of activities of daily living function.[199] In the latter study no 
significant difference in terms of neuropsychological scores could be recorded 
between supplement group with methylcobalamin and folic acid for 24 
months and placebo in patients with mild to moderate Alzheimer’s 
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disease.[200] Therefore, we are now confronting a dilemma. Observational 
studies strongly support the association between Hcy and cardiovascular or 
cerebrovascular diseases. And reliable biological mechanisms have been 
indicated the pathogenetic role of Hcy. However, most intervention trials have 
failed to show any significant clinical benefit from Hcy reducing therapy. In 
that case it seems reasonable to propose the question to whether Hcy has 
definitely been successfully reduced.[201] In order to answer the question 
the relationship between Hcy and deep venous thrombosis or pulmonary 
embolism was conducted in nearly 10 thousand participants of the 5-year 
Fenofibrate intervention and event lowering in diabetes trial.[202] 
Fenofibrate is a lipid regulating agent of the fibrate class. The preliminary 
results of the study have already highlighted a slightly higher incidence of 
pancreatitis, deep venous thrombosis, and pulmonary embolism associated 
with the drug.[203] In this analysis, the level of Hcy significantly increased by 
6.5 μmol/L during the fenofibrate therapy. And a change was fully invertible 
in the placebo group but lasted in the experimental group until reversing at 
the end of therapy.[202] The interaction between hyperhomocysteinemia and 
fenofibrate was greater in patients with the highest baseline Hcy levels, which 
provides a reasonable clue on the existence of a biological interaction 








Figure 1-2 Homocysteine metabolism showing metabolic pathways  
The metabolism of Hcy is generally at the intersection of two metabolic 
pathways: remethylation and transsulfuration.  
 
Hcy is a non-protein forming amino acid so cannot be codiﬁed in DNA. Mainly 
it is characterized by containing sulfur and formed from the essential 
methionine, through the methylation process, so it is basically an 
intermediary in the metabolism of methionine and cysteine. The metabolism 
of Hcy is generally at the intersection of two metabolic pathways: 
remethylation and transsulfuration. In remethylation, a methyl group from N-
5-methyltetrahydrofolate or from betaine is necessary for homocysteine to 
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form methionine. The reaction with N-5-methyltetrahydrofolate happens in 
all tissues and it is dependent of vitamin B12, whereas the reaction with 
betaine is confined mainly to the liver and it is independent of vitamin B12. A 
part of methionine is then converted to form S-adenosylmethionine (SAM) at 
the presence of activated ATP. SAM acts in the capacity of a universal methyl 
donor to a variety of acceptors. S-adenosylhomocysteine (SAH), the by-
product of these methylation reactions, is following hydrolyzed to regenerate 
Hcy. And then a whole cycle of methyl-group transfer is completed. It is 
important to note that this hydrolysis is a reversible reaction favoring the 
synthesis of SAH, and that elevated cellular concentrations of this metabolite 
are prone to precede and accompany all forms of hyperhomocysteinemia. In 
the transsulfuration, homocysteine concentrates with serine to form 
cystathionine in an irreversible reaction catalyzed by a pyridoxal-5′-phosphate 
(PLP) enzyme, specifically CBS. Cystathionine is hydrolyzed by a second PLP 
containing enzyme, γ-cystathionase, to generate cysteine and α-ketobutyrate. 
And the extra cysteine is oxidized to taurine or inorganic sulfates or is 
excreted in the urine. Thus the transsulfuration pathway effectively 
catabolizes excess homocysteine in addition to the synthesis of cysteine and 




Cysteine is converted to H2S by three enzymes which are cystathionine β-
synthase (CBS), cystathionine γ-lyase (CSE) and 3-mercaptopyruvate 
sulfurtransferase (3MST).[205-207] Consequently H2S is either released 
immediately following catalyzed generation by the three enzymes or stored 




Figure 1-3 Cysteine metabolism 
Three principal metabolic pathways are shown. 
 
1.2.4.2.1. Pyridoxal-5′-Phosphate (PLP)-Dependent 
Enzymes  
 
Cysteine can be metabolized to H2S by pyridoxal-5′-phosphate (PLP)-
dependent enzymes, including CBS and CSE which are expressed in many 
tissues such as the liver and the kidney.[209-212] CBS pathway can be 
suppressed by CBS inhibitors including hydroxyl amine and aminooxyacetate 
while CSE pathway can be suppressed by CSE inhibitors including 
propagylglycine and β-cyanoalanine. A CBS activator, S-adenosyl methionine, 
enhances the metabolism of cysteine via CBS pathway.  
 
1.2.4.2.1.1. Cystathionine β-Synthase  
 
CBS is a tetramer and comprises 551 amino acids with a subunit molecular 
weight of 63kDa.[213] It has been shown that CBS is mainly localized to 
cerebellar Bergmann glia and astrocytes in the brain.[214, 215] CBS was 
expressed in neuroepithelial cells in the ventricular zone at early 
developmental stages and in radial glial cells or astrocytes at the late 
embryonic and neonatal stages. CBS can be upregulated by epidermal growth 
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factor (EGF), transforming growth factor-α (TGF-α), cyclic adenosine 
monophosphate (cAMP), and dexamethasone in reactive astrocytes. Cultured 
astrocytes synthesize H2S from cysteine at the rate of 15.06 μM/gram 
protein/h, which is around 7.57-fold faster than microglial cells do.[216] 
Inflammatory activations of astrocytes and microglia downregulate the 
expression of CBS, leading to the subsequent reduction of H2S production. In 
the other part of the brain, the localization of CBS is reported in Purkinje and 
hippocampal neurons, whereas whether CBS is localized to neurons is still 
controversial.[215, 217] CBS was well thought of in ischemic stroke, but it is 
found that no significant difference in expression of CBS or CSE between 
sham-operated and pMCAO rats.[218]  
  
Trisomy 21 is the most common syndrome clinically involved to mental illness. 
In human, CBS is encoded on chromosome 21 (21q22.3). And it is reported 
that a polymorphism of CBS allele is remarkably underrepresented in children 
with high intelligence quotient. But the mechanism by which a functional 
genetic variant in the CBS gene may affect cognitive function remains to be 
determined.[219] CBS is localized to astrocytes and those surrounding senile 
plaques in the brains of Trisomy 21 patients with Alzheimer's disease. And the 
levels of CBS in Trisomy 21 patients are approximately 3-fold greater than 
those in the normal, which may result in the developmental abnormality in 
cognition in Trisomy 21 children and that may lead to Alzheimer's disease in 
adults.[214] As CBS is an important enzyme in homocysteine and cysteine 
metabolism, CBS deficiency causes homocysteinemia, which is a graded risk 
factor for chronic heart failure and seizures. It is found that the upregulation 
of hypothalamic NMDA receptors may lead to heart failure. On the contrary, 
downregulation of the NMDA receptors reduces homocysteine related 
damage in neurons as well as the heart rate induced by NMDA analog, 
indicating that homocysteine is an agonist to NMDA receptors. 
Homocysteinemia has been reported to activate mitochondrial matrix 
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metalloproteinase. The activation induces structural remodeling and results 
in myocyte mechanical dysfunction by agonizing NMDA receptors.[220] 
 
1.2.4.2.1.2. Cystathionine γ-Lyase 
 
Unlike CBS, CSE is expressed in the thoracic aorta, ileum, portal vein, uterus, 
pancreatic islets and the placenta.[206, 221, 222] But in the situation of 
hybridization CSE is also expressed in smooth muscle rather than in 
endothelium of the thoracic aorta.[212, 223] And it is found via 
immunohistochemistry and Western blot analysis that CSE is primarily 
localized to thoracic endothelium of mice, bovine, and humans with faint 
staining in smooth muscle.[224] This observation indicates that H2S is 
produced by CSE localized to vascular endothelium instead of thoracic aorta 
and may play a role as a component of EDRFs. The expression of CSE can be 
elevated by the NO donor, S-nitroso-N-acetylpenicillamine (SNAP) and 
enhanced by sodium nitroprusside (SNP).[223] It is also shown that CSE 
activity is also regulated by calcium-calmodulin by binding to calmodulin.[224] 
And the process is abolished by EGTA and the calmodulin antagonist W7. H2S 
genesis from cysteine in endothelial cells is magnified by a calcium ionophore 
A23187 and blocked by a calcium chelator BAPTA. CSE catalyzes cysteine or 
homocysteine to convert to H2S. Usually, 70% of H2S is produced from 
cysteine and the other 30% is from homocysteine. However, under conditions 
with higher levels of homocysteine such as homocysteinemia, homocysteine 
becomes the primary source of H2S production instead of cysteine.[225]  
 
 
1.2.4.2.2. 3-Mercaptopyruvate Sulfurtransferase 
 
3MST was found catalyzing cysteine to convert to H2S in brain homogenates 
of even CBS knockout mice, indicating that 3MST probably is another H2S-
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producing enzyme in the brain.[205] The enzymatic activity requires a 
fraction of synaptosome and mitochondria and a substance with molecular 
weight less than 3kDa in a cytosol fraction. 3MST with cysteine 
aminotransferase (CAT), the same as aspartate aminotransferase (AAT), can 
produce H2S from cysteine in the presence of α-ketoglutarate.[226] However 
the pathway have not been thought producing H2S in a large way because the 
activity of 3MST along with CAT hits the maximum at pH 9.7 which is an 
alkaline condition and rarely reached in the physiological conditions.[209] 
Moreover 3-mercaptopyruvate (3MP), an intermediate product of 3MST, is 
unstable and has not been identified in tissues. 3MST and CAT are reported to 
localize to mitochondria and a substance with molecular weight less than 
3 kDa in cytosol fraction is α-ketoglutarate. The production of H2S from 
cysteine via 3MST pathway is suppressed by competition with aspartate, a 
primary substrate for CAT or AAT, in a dose-dependent manner. The 
intermediate product of 3MST and H2S, 3MP, has not been identified. The 
existence of 3MP has been suggested based on the observation of a 
metabolite of 3MP, mercaptolactate-cystene disulfide which is identified in 
urine. The pathway produces H2S even without the addition of 3MP, 
indicating the existence of 3MP. In the brain the localization of 3MST is in 
neurons, including hippocampal pyramidal neurons, cerebellar Purkinje cells, 
and mitral cells in the olfactory bulb.[223] In the thoracic 3MST is localized to 
both endothelium and smooth muscle, and CAT is localized only to 
endothelium, suggesting that In this pathway 3MST catalyzed H2S in vascular 
endothelium may function as a component of EDRFs.[223]  
 
3MST has been reported being faster than CBS in terms of H2S production 
from cysteine. Previously CBS was thought to be the unique H2S-producing 
enzyme in the brain. The prominent difference between 3MST and CBS is that 
3MST produces bound sulfane sulfur more efficiently than CBS does.[223] 
This is also the first established enzyme that produces H2S and generates 
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bound sulfane sulfur as a reservoir of H2S in the cells. The reason between 
3MST and CBS in terms of the distinct efficiency of producing bound sulfane 
sulfur may be because 3MST has two third homology with rhodanese which 
has sulfur-carrier activity from bound sulfane sulfur to acid-labile sulfur. In 
that case it is possible that 3MST has the sulfur-carrier activity from H2S to 
bound sulfane sulfur while CBS does not.  
 
3MST can also catalyze the reaction to convert 3MP and SO32− to thiosulfate 
and pyruvate. This reaction can be catalyzed by rhodanese. And the 
application of Na-thiosulfate to the mouse model of heart failure prevented 
the decline in cardiac function. Thiosulfate may modulate cardiac dysfunction 
by increasing ventricular H2S generation.[227] 
 
1.3. Hydrogen Sulfide 
 
It is a colorless gas with the characteristic foul odor of rotten eggs. And it is a 
well-known toxic gas so that it has been assumed to exist in animal tissues 
only at very low concentrations even though it could be produced 
endogenously by enzymes and non-enzymatic pathways. However recently it 
has been shown that H2S production in mammalian tissues is more influential 
than it was first expected. The concentrations of H2S were around 50-160 
µmol/L. But physiologically a concentration of H2S around 10-130 µM is 
enough to enhances N-methyl-D-aspartate (NMDA) receptor-mediated 
responses and facilitate the induction of hippocampal long-term potentiation 




H2S is the sulfur analog of water with a molecular weight of 34.08, which is 
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slightly heavier than air. Relative to water, H2S has intermolecular forces and 
then exist in gaseous form at room temperature and pressure. It can be 
oxidized by a variety of agents for form sulfur dioxide (SO2), sulfates such as 
sulfuric acid and elemental sulfur. In the mammalian body, at a physiological 
pH of 7.4, approximately 30% of H2S exists as the undissociated form and 70% 
as the hydrosulfide anion (HS-).[228] It can easily penetrate the plasma 
membranes of cells in the undissociated form because of its lipid solubility. 
Although it has not been possible to determine which form of H2S (H2S, HS−, 
or even S2−, the mix of free inorganic sulfides) is active, the term “hydrogen 




The toxicity of H2S was noticed since the first description in 1713.[228] Lot of 
works had been done to investigate H2S toxicity by H2S exposure because it is 
still a pollutant sources and a working hazard in modern world. This toxic gas 
has often been thought to be a broad spectrum toxicant since most organ 
systems are susceptible to the effects of H2S. The early symptoms of H2S 
exposure include sore throat, dizziness, nausea, and respiratory effects 
caused by airway irrigation. Long term exposure to H2S exhibits a very steep 
dose-response relationship with an LD50 of 15 mg/kg (rats), especially for CNS 
and respiratory depression, which is the major cause of H2S related 
death.[229] The primary cause of death in H2S poisoning has been reported 
to respiratory paralysis as a result of the toxic effect of sulfides on the 
respiratory centers of the brain.[230] Additionally, pulmonary edema has 
consistently been reported as the single most notable lesion in autopsies of 
individuals killed by this gas.[231] Mechanistically, it is believed that the H2S 
poisons the mitochondria at low endogenous levels via reversible inhibition of 
cytochrome c oxidase. Under the condition of H2S toxicity, memory loses are 
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common in survivors of sulfide poisonings. In the brain, acute intoxication 
with H2S inhibits monoamine oxidase and changes the levels of 
neurotransmitters.[229] The toxic effects of H2S in vitro such as on neurons 
were also studied by electrophysiological approaches in dorsal raphe 
serotonergic cells. And it was found that sulfide activates calcium channels as 
well as calcium dependent potassium channels and suppresses the delayed 
rectifier.[232]  
 
1.3.3. Endogenous H2S 
 
The levels of free H2S in the brain have been measured.[208, 233] It has been 
found that monobromobimane binds to thiols and mixes with brain 
homogenates. And the amount of monobromobimane specifically bound to 
H2S measured by mass spectroscopy is around 8 μM. In the second method in 
which brain homogenates were forcefully mixed with phosphate buffer and 
free H2S evaporated into the air is detected because the evaporation of H2S 
can be initiated at pH 6.0 where more than 95% of H2S exists in the form of 
gas. The levels of free H2S is around 14 nM and 17 nM in the brain and in the 
liver respectively.[233] In the third method, brain homogenates were mixed 
with crush silver, which absorbs H2S as silver sulfide on the surface of silver 
particles which were later fully washed since the adhered brain homogenates 
on the surface of silver particles would release H2S under acidic conditions. 
The powdered silver was transferred into small tubes filled with nitrogen gas. 
It was followed that thiourea and H2SO4 were applied to release H2S. The 
minimal detectable level of H2S in this method is 25 nM/tube, corresponding 
to 9.2 μM in the brain. Since H2S was not detected in this method, free H2S, if 
is suggested less than 9.2 μM in the brain.[208] Similarly to NO, free H2S is 
maintained low in the basal condition and a repetitive application of H2S to 
astrocytes decreases the responses to H2S, indicating the desensitization of 
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the sensitive molecule to H2S, and low levels of H2S in the basal condition 
probably takes the favor to properly respond to H2S release.[234] One gram 
of H2S is dissolved in 242 ml of H2O and dissociates to H+ and HS− with a PK1 
6.76 at 37°C, and approximately 85% of H2S is in the form of gas. So in order 
to measure free H2S as gas, dissolved HS− and S2− are changed into H2S gas by 
shifting the equilibrium into acidic conditions. The fourth method to detect 
H2S concentration is reaction with N,N-dimethyl-p-phenylenediamine sulfate 
with FeCl3 in high concentrations of HCl and methylene blue.[235] In this 
method, H2S released from reaction mixture containing tissue homogenates 
were trapped with center well filled with zinc acetate solution and the 
reaction is stopped by trichloroacetic acid. Because the amount of H2S 
produced by enzymatic reaction is abundant, this method can be applied. In 
contrast, this method is not appropriate to measure endogenous levels of 
free H2S that are much lower than that released from acid-labile sulfur. In 
order to solve this problem, recently the fifth method, a fluorescence-based 
assay was invented in this field because of the high sensitivity and 
convenience. In the assay, H2S is considered as a nonsubstituted thiol and 
undergoes nucleophilic reaction twice, whereas other thiols such as cysteine 
are monosubstituted thiols that can only undergo nucleophilic reaction once. 
And compounds containing bis-electrophilic enters was used as reagents for 
H2S detection. So the H2S-mediated benzodithiolone formation under mild 
conditions has been proved to be selective for H2S and it did not proceed with 
other biological thiols such as cysteine and glutathione. Using this strategy, 
the concentration of H2S can not only be measured by the fluorescence signal, 
but also be assessed from the analysis of the benzodithiolone product. We 
are now actively pursuing more specific H2S fluorescent probes based on this 
new benzodithiolone formation and related reactions.[236]  
 
The levels of acid-labile H2S is mainly sulfur atoms in iron sulfur complexes, 
which plays an important role in a wide range of redox reactions in enzymes 
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of the respiratory chain in mitochondria and is released at physiological pH 
5.4.[237] However in mitochondrial H2S may be difficult to be released from 
acid-labile sulfur under physiologic conditions as pH is generally greater than 
7 and usually does not become acidic. When Iron sulfur complexes are 
detached from enzymes by detergents and protein denaturants, they are 
unstable and readily release H2S.  
 
1.3.4. Physiological Role 
 
H2S was thought to be a toxic gas rather than have any physiological function 
for a long time, but the possibility of H2S as a physiological factor cannot be 
ignored since it has been found and presented in mammalian tissues at 
relatively high level. The sulfide levels in the brain have been detected in rats, 
humans, and bovine, suggesting that H2S may have a physiological 
function.[229, 238, 239] Some studies spur the exploration of the 
physiological function of H2S although initially the sulfide levels was 
recognized and measured as the amounts of H2S released from acid-labile 
sulfur.[208] H2S was first demonstrated as a neuromodulator in the brain. CBS 
is expressed in the brain and produces H2S. This production is enhanced by a 
CBS activator, S-adenosyl methionine, and is suppressed by CBS inhibitors 
such as AOAA and HA. And H2S facilitates the induction of hippocampal LTP by 
enhancing the activity of NMDA receptors.[207] The involvement of H2S and 
CBS has also been shown in the adjustment of a hormone release. The 
release of corticotropine-releasing hormone (CRH) is inhibited by H2S, and S-
adenosyl methionine which is an activator of CBS exhibits a similar effect on 
CRH release to H2S.[240] H2S was later found to activate ATP-dependent K+ 
channels and mediate smooth muscle relaxation of human corpus 
cavernosum.[212, 241] Basically the function of H2S is mainly on nervous 




1.3.4.1. Nervous System 
 
 
Figure 1-4 Physiological Roles of H2S in nervous system  
H2S may act as a neuromodulator and neuroprotectant. A lot of studies have 
been done to investigate the role of H2S and further research is still necessary 




Gasotransmitters have been identified in certral nervous system for a long 
time. The ﬁrst toxic gas identiﬁed as a signal molecule is nitric oxide (NO), 
which is produced from arginine by NO synthase.[242] Another toxic gas, 
carbon monoxide (CO), is produced from biliverdin by heme oxygenase.[243] 
Both NO and CO were identiﬁed as smooth muscle relaxants, and recognized 
later as neurotransmitters.[244, 245] Hydrogen sulﬁde, which is produced 
from cysteine or homocysteine, was also found to be a neuromodulator.[210] 
It was hypothesized to have a physiological function in the brain as it induced 
hippocampal LTP when it was applied associatively with a weak tetanic 
stimulation, which alone does not induce LTP.[210] It is also shown that H2S 
suppressed synaptic potentials and modified K+ channels despite its 
toxicity.[232] Also it is indicated that excitatory post synaptic potentials 
(EPSPs) are suppressed at high toxic levels of H2S but not affected at low 



















levels. In occlusion experiments, the mechanism for LTP induced in the 
presence of H2S is similar to LTP induced by a regular stimulation. H2S 
activates LTP at active, which may be involved in associative learning as 
defined by Hebb. Although H2S, a member of gaseous messengers, facilitates 
the induction of LTP, the mechanism of action of H2S is different from the 
others such as NO and CO. It is well established that the activation of NMDA 
receptors is required for the induction of LTP. NMDA receptor is not necessary 
for NO and CO for the activation while it has to be blocked to facilitate the LTP 
induction by H2S.[246] H2S enhances the currents mediated by NMDA 
receptors. Another apparent difference is that H2S does not activate soluble 
guanylyl cyclase and increase intracellular cGMP whereas NO and CO do.[243] 
Some data show that glia also have neurotransmitter receptors and respond 
to transmitters, which is on the contrary of previous findings. It is suggesting 
that there are probably reciprocal interactions between neurons and glia. 
Neural activity evokes glial calcium waves while glial calcium waves drive 
neuronal activity. Glia communicate with each other via increasing 
intracellular levels of Ca2+ and propagate the signal as Ca2+ waves which are 
usually prone to be initiated at sites of contact with neurons, suggesting that 
glial Ca2+ waves are probably initiated by neuronal excitation.[247] Similarly 
astrocytes also respond directly to a neurotransmitter released from neurons. 
In neurons, H2S enhances the activity of NMDA receptors activated by 
glutamate while H2S increases intracellular concentrations of Ca2+ by mainly 
increasing Ca2+ influx in astrocytes.[234] However, there is a question. When 
neuronal excitation induces Ca2+ waves in astrocytes to modulate their 
activities, the transmission speed is different. The neuronal transmission is 
fast, while Ca2+ waves propagate slowly. It is probably because of a time 
delayed signal transmission. Specifically, when an electrical stimulation of 
mossy fiber induces two distinct types of signal propagation from CA3 to CA1, 
a fast signal transmits from CA3 directly to CA1. And a delayed signal 
propagates from CA3 to CA1 mediated through CA2.[248] La3+, Gd3+, and 
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ruthenium red channels may be activated by H2S since they are blockers of 
voltage-dependent Ca2+ channels and suppresses H2S responses. TRP 
channels have also been demonstrated to be involved in the responses to H2S. 
Contraction of the detrusor muscle is induced by H2S is suppressed by 
unselective TRP channel blocker, ruthenium red and regulated by capsaicin-
sensitive primary afferent neurons in the urinary bladder. However the 
contraction is not influenced by capsazepine, SB366791 or specific TRPV1 
channel blocker, indicating some type of TRP channels other than TRPV1 
channels may be involved in the responses to H2S.[249] Specifically, H2S Also 
provokes neuropeptide release in the airways but it is remarkably attenuated 
by capsazepine. On the other hand, contraction induced by H2S in the airways 
is also suppressed by SB366791, capsazepine and ruthenium red, suggesting 
the involvement of TRPV1 channels in contraction induced by H2S. CHO cells 
expressing TRPA1 channels also respond to NaHS.[250] These observations 
suggest that TRP channels are H2S -sensitive molecules or receptors. 
Additionally, H2S production tends to be increased by pMCAO despite the 




KATP channels are associated with protection against ischemia and 
excitotoxicity.[251] The channel activator reduces abnormal excitatory 
synaptic activity and is protective against neuronal death. And unsurprisingly, 
these protective effects are reduced by KATP channel blockers glibenclamide 
and glipizide.[252] Pinacidil suppresses glutamate toxicity and the protection 
is increased by the simultaneous application of H2S. However a blocker to 
mitochondrial KATP channels which is 5-hydroxydecanate does not modulate 
protection by H2S. KATP channels localize to plasma membrane rather than to 
mitochondria, which may mediate H2S induced neuroprotection. CFTR Cl− 
channels and sulfonylurea receptors belong to the ATP-binding cassette 
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superfamily. Both of the groups share significant sequence homologies.[253] 
The Cl− channel blockers, NPPB and IAA-94, suppress protection by H2S and 
levamisole which is an opener of Cl− channels, efficiently suppresses 
glutamate toxicity, suggesting that CFTR Cl− channels are also associated with 
protection by H2S against oxidative stress. It also reported that homeostasis 
of transmembrane Cl− gradients is required for normal cell survival.[254] In a 
cloned hippocampal neuronal cell line, HT22 cells, H2S protects cells mainly by 
enhancing the activity of KATP and CFTR Cl− channels while in primary cultures 
of neurons H2S protects cells from oxidative glutamate toxicity mainly by 
increasing glutathione levels.[252, 255] KATP channels are highly expressed in 
neurons of the hippocampus, and expression of CFTR is greater in the 
hippocampus than in the cortex.  
 
H2S enhances the activity of cysteine or glutamate antiporter to increase the 
levels of cysteine which is a substate for glutathione synthesis.[255] Moreover, 
cysteine, normally exists as cystine, is also efficiently transported into cells by 
H2S. Cystine is the oxidized form of cysteine in extracellular space. However, 
the level of cysteine is around 20 μM in plasma and blood. As a reason that 
transporters of cysteine are widely distributed in various types of cells, 
cysteine can readily be imported into cells and used for glutathione 
production when extracellular cystine is reduced into cysteine in the presence 
of H2S, considering H2S readily passes through the plasma membrane.[256] 
Two kinds of glutamate toxicity are nonreceptor-mediated oxidative 
glutamate toxicity and ionotropic receptor-initiated excitotoxicity.[257] 
Oxidative glutamate toxicity is a well-established cell death pathway that is 
independent of ionotropic glutamate receptors, which has been observed in 
primary cultures of neuronal cells, neuronal cell lines and brain slices.[252, 
255, 257] Oxidative glutamate toxicity is initiated by high levels of glutamate 
in cultures of neurons that have not yet expressed ionotropic glutamate 
receptors and is not suppressed by the antagonists of ionotropic glutamate 
43 
 
receptors. Glutamate and cystine have the same amino acid transporter and 
they compete for the transport into cells.[258] So it has been suggested that 
high level of extracellular glutamate inhibits the transport of cystine which 
should be the primary source of intracellular cysteine necessary for 
glutathione synthesis. Glutathione is a major antioxidant in the cellular 
defense against oxidative stress since the intracellular concentrations of 
cysteine are considerably lower than those of glutamate and glycine. 
Nevertheless H2S increases the levels of glutathione, which is a cellular major 
and potent antioxidant.[255] Cellular GSH is mostly localized to the cytoplasm, 
and stored in mitochondria. H2S increases the total cellular levels of GSH and 
also the pool in mitochondria. H2S also protects cells from broader oxidative 
stress besides the protection from oxidative pathway glutamate toxicity.[256] 
H2S stabilizes mitochondrial membrane potential and regulates JNK-MAPK by 
suppressing cell death induced by rotenone.[259] The in vitro found that H2S 
protects brain by reinstating GSH levels decreased by oxidative stress. Brains 
of only one quarter of fetuses were macerated by a treatment of NaHS before 
the ischemia-reperfusion while all fetal brains 24 h after reperfusion from 
ischemia were macerated and the GSH levels in the fetal brains were severely 
decreased. Nonmacerated brains were maintained mostly out of a control 
though the GSH levels of macerated brains were decreased. H2S protects fetal 
brains by reinstating the GSH concentrations suppressed by intra-utero 
ischemia-reperfusion. H2S enhances two enzymes which are γ-glutamyl 
cysteine synthetase (γ-GCS) and glutathione synthetase (GS), resulting in the 
reduction of glutathione and the increase of glutathione levels. When cells 
are exposed to H2S, the activity of γ-GCS is enhanced, indicating that H2S may 
activate some sensitive molecule or receptor to induce an intracellular signal 
that may enhance the activity of the enzyme, whereas the activity of GS is not 
influenced by H2S. However some studies claim that H2S production may 




1.3.4.2. Smooth Muscle 
 
It was found that there was a synergy between NO and H2S on smooth muscle 
relaxation.[211] In addition to the synergistic effect, a similar synergistic 
effect between H2S and NO was observed that the twitch responses of the 
ileum to electrical stimulation is inhibited and  CSE activity is also enhanced 
by NO.[260]  And also sodium nitroprusside (SNP) and S-nitroso-N-
acetylpenicillamine (SNAP), both are NO donors, increased the production of 
H2S and expression of CSE.[212] And also H2S stimulates endothelial cells to 
release certain factors that facilitate the relaxation of smooth muscle, 
supporting that H2S enhances relaxation activity of NO.[261] Also it’s been 
found that peripheral arteries normally operate at lower O2 concentrations 
than the aorta and that H2S efficiently vasorelaxes arteries under low O2 
conditions.[262] And when the bound NO is effectively reduced and liberated, 
S-nitrosothiols in vascular tissue may also contribute to vessel tone. This kind 
of vasorelaxation by H2S is stimulated by opening ATP-dependent K+ channels 
in a non-ATP-associated manner.[212] However sometime it is observed that 
the vasorelaxation effect of H2S was enhanced by the interaction of 
exogenously applied H2S with endothelium-derived relaxing factors, including 
EDRF and EDHF, which is supported by the finding that the application of L-
NAME and the co-application of charybdotoxin and apamin  reduced the H2S-
induced vasorelaxation. Another possibility is corpus cavernosum which is a 
highly vascularized tissue and its function depends on an equilibrium 




Mostly the biosynthesis of H2S has already been covered in cysteine 
metabolism. Simply speaking, H2S is produced by three enzymes, 
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Cystathionine β-synthase (CBS), Cystathionine γ-lyase (CSE) and 3-
mercaptopyruvate sulfurtransferase (3MST). CBS, which is a pyridoxal-5’-
phosphate (PLP)-dependent enzyme, catalyzes a β-elimination reaction from 
cysteine to produce H2S. It also catalyzes the condensation of homocysteine 
with cysteine.[263] CSE emerged as an enzyme responsible for the generation 
of H2S in thoracic aorta, ileum and portal vein, resulting in smooth muscle 
relaxation.[211] Under most circumstance, CSE catalyzes the production of 
H2S mainly from the amino acid cysteine, but when homocysteine levels are 
high, such as in  homocysteinemia, homocysteine is the preferred 
substrate.[225] 3-mercaptopyruvate sulfurtransferase (3MST) can produce 
H2S from 3-mercaptopyruvate, produced by cysteine aminotransferase (CAT). 
However, the expression of 3MST has not been investigated in detail. It has 
been suggested that it is expressed in the brain as well as arterial 
endothelium and smooth muscle. Since in arteries CAT is localized to 
endothelium but not smooth muscle, it is likely that only the endothelium can 
produce H2S through the 3MST pathway.[223] 
 
1.4. Knowledge Gaps and Study Objectives 
 
Based on the above review of the relationship between stroke, homocysteine, 
and H2S, we know that elevated cysteine and H2S aggravate ischemic stroke, 
pMCAO increases H2S production in the brain, there is no difference in the 
expression of CBS and CSE after pMCAO, and how H2S is biosynthesized in the 
brain. However unfortunately some research gaps for the current study still 
exist and are summarized below: 
 Although homocysteine, cysteine and H2S have been reported to be 
risk factors of stroke, the main H2S-producing enzyme and the 
regulation system is unknown.  
 Although MCAO increases H2S production in the brain, gene and 
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protein expressions of CBS and CSE in brain tissues remain unchanged. 
It is hard to explain as CBS and CSE were previously thought as two 
unique H2S-producing enzymes in the brain.  
 There is little research on regional H2S-producing enzyme activities in 
the brain. And the major source of H2S production via either CBS or 
3MST is still controversial.  
 There is little research on 3MST regional and cellular localization in the 
brain, and the existing cellular localization is deduced by morphology 
instead of a more conclusive double staining.  
 No data on 3MST expression in the brain before or after stroke despite 
its importance of catalyzing H2S production.   
 The current methods for the detection of H2S, such as colorimetric 
assays, gas chromatography, and polarography analysis, require the 
homogenization and extraction from cells and tissues. However, the 
rapid diffusion of H2S influences the accuracy of the estimation of H2S 
concentration. Additionally, endogenous levels of sulfide have been 
measured in the brains of rats, bovines and humans, but relatively 
high concentrations of hydrochloric acid or trichloroacetic acid were 
generally used to release H2S in these studies. Therefore, the amounts 
measured were not free H2S actually, but H2S released from acid-labile 
sulfur since the critical pH to release H2S from acid-labile sulfur is 5.4. 
Acid-labile sulfur is localized mainly to mitochondria which usually do 
not become acidic. In that case, the value of the current study might 
be limited by the discrepancy between experimental and physiologic 
conditions.  
 
The objective of the study is to indicate a possible mechanism of the 
relationship between stroke and homocysteine which is the established risk 
factor of stroke, and to identify the key H2S-producing enzymes after cerebral 
ischemia. The specific objectives of my research are to: 
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 Investigate regional H2S-producing enzyme activities in the brain.  
 Explain why protein expressions of CBS and CSE in brain tissues 
remain unchanged after stroke, and try to find out the other possible 
pathway that causes the elevated H2S level after cerebral ischemia.  
 Study on 3MST regional and cellular localization in both rats and mice.  
 Establish an experimental stroke model with consistence, ease and 
high neurological severity score.  
 Investigate 3MST expression and localization in vivo before and after 
experimental stroke.  
 Investigate 3MST expression and localization in vitro under oxygen-
glucose deprivation.  
 Measure H2S concentration in primary astrocytes and stain H2S with 









All of the animals were obtained from University Laboratory Animal Center 
and housed in groups. All of the animal experimental procedures in this study 
were approved by IACUC (Institutional Animal Care and Use Committee) of 
the National University of Singapore and all efforts were made to minimize 
suffering and the number of rats in all experiments.  
 
2.2. Middle Cerebral Artery Occlusion 
 
2.2.1. Permanent Middle Cerebral Artery Occlusion 
Model 
 
Male Sprague Dawley rats (250-280 g) were randomly assigned into pMCAO 
group or sham control group. A subtemporal approach was used to induce 
the permanent occlusion of the left middle cerebral artery (MCA). [75, 218] 
The rats were anaesthetized with ketamine (75 mg/kg, i.p.) and xylazine (10 
mg/kg, i.p.). A craniectomy was extended dorsally up to the first major branch 
of the MCA. Then the dura was opened with a bent 26-gauge needle and the 
arachnoid membrane was carefully removed. The MCA was cauterized with 
an electrocauterizer without damaging the brain surface and then cut. The 
site of the occlusion was between the inferior cerebral vein and olfactory 
tract. The sham group was operated in the same way as the experimental 




2.2.2. Filament Middle Cerebral Artery Occlusion 
Model 
 
Rats were anesthetized with 1% to 2% isoflurane under spontaneous 
respiration in a 30% oxygen/70% nitrous oxide mixture. Rectal temperatures 
were maintained between 37°C and 38°C with a thermostat-controlled 
heating pad. The whole process was under an operating microscope. The left 
common carotid artery (CCA) was exposed through a midline incision. All 
other branches were isolated and coagulated along with the terminal lingual 
maxillary artery branches. The internal carotid artery (ICA) was then isolated 
and its extracranial branch, the pterygopalatine artery, was ligated close to its 
origin. Thus, the ICA, which was the only extracranial branch of the CCA, 
remained open. A 3 cm length of 3-0 nylon suture with a slightly enlarged and 
rounded tip was inserted into the transected lumen of the external carotid 
artery (ECA), and gently advanced from the ICA across to the opening of the 
MCA. The distance from the tip of the suture to the bifurcation of CCA was 
17-19 mm. Laser-doppler flowmetry was used to monitor the reduction of 
regional cerebral blood flow (Figure 2-1). For reperfusion, the suture was 
withdrawn into the ECA to restore ICA-MCA blood flow. The skin was sutured 






Figure 2-1 rCBF in the ischemic cortex after filament MCAO 
The diagram shows the time course of ischemia. Changes in cerebral blood 
flow are measured by a laser Doppler flowmeter as mentioned previously. 
Before pushing in, the CBF is around 100%. As the filament pushed in, the 
MCAO is started and the CBF begins to drop. In the blood flow obstruction 
period, the CBF remains a low level and consistent. After 1 or 1.5 hours, the 
ischemia stops due to the removal of the ligations. And blood flow starts to 





2.2.3. Thromboembolic Middle Cerebral Artery 
Occlusion Model 
 
Animals were anesthetized with 1-2% isoflurane under spontaneous 
respiration in a 30% oxygen/70% nitrous oxide mixture. Physiological 
parameters, including rectal temperature, mean arterial blood pressure, pH, 
pCO2, and pO2, were monitored throughout the experiment. 
 
2.2.3.1. Preparation for Thromboembolic Model 
 
2.2.3.1.1. Homologous Clot Preparation 
 
 A donor rat was anesthetized using the method mentioned above 
 Femoral artery was cannulated and blood was withdrawn into 50 cm 
of PE-50 tubing  
 The clot  was kept in the tube for 2h at room temperature, and 
subsequently retained for 22h at 4°C  
 
2.2.3.1.2. PE-50 Catheter Modification 
 
Modified PE-50 catheter was made for injecting the clot: 
 PE-50 tube was cut into 40-50 cm 
 Both ends of the tube were held with forceps 
 The middle of the tube was heated with a heating lamp, and then the 
heated tube was pulled and tempered (the tip of the catheter of 0.3 
mm outer diameter was made) 
 The middle of the tube was cut where the point was tempered to get 




2.2.3.2. Thromboembolic Model 
 
2.2.3.2.1. Settlement and Measurement of rCBF 
 
Measuring rCBF with laser Doppler flowmetry (LDF) was necessary to 
evaluate the reduction of CBF during MCA occlusion and also to document 
the degree of reperfusion after thrombolysis with tPA or other thrombolytic 
agents. A donor rat was anesthetized using the method mentioned above: 
 An incision  was made in the midline of the scalp 
 The temporal muscle was dissected from the bone with forceps, 
scissors, and dissector 
 The bone was thinned at 2 mm posterior and 6 mm lateral to the 
bregma by drilling 
 The LDF probe was placed with glue to start monitoring rCBF 
 
2.2.3.2.2. Physiological Monitoring and Venous Line 
for Injection 
 
 Rectal temperatures were maintained at 37 ± 0.5°C with a thermostat-
controlled heating pad 
 The femoral artery was cannulated and monitored for physiological 
parameters such as mean arterial blood pressure, pH, pCO2, and pO2 
during the experiment  
 The femoral vein was also cannulated for drug administration such as 
tPA 
 
2.2.3.2.3. Preparation for Injecting the Clot 
 
 The PE-50 tubing containing the clot was cut to the optimal length (3-
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5 cm) and connected to a 3-ml syringe filled with saline with a 23 G 
needle 
 The clot was transferred into a dish filled with saline (Figure 2-2a) 
 The clot was aspirated into a 30-cm PE-10 tube with a 3-ml syringe 
and 30G needle and the clot was moved back and forth (wash) five 
times in the PE-10 tube (Figure 2-2b) 
 The PE-10 tube was connected to the bottom of the modified PE-50 
catheter and the clot was shifted into the modified PE-50 catheter 
(Figure 2-2c) 
 A 1-ml syringe was connected with 23 G needle to the bottom of the 






Figure 2-2 Preparation for injecting the clot 
a. Transfer of the clot into a dish filled with saline from the PE-50 tube. b. 
Aspiration of the clot into a 30-cm PE-10 tube and washing of the clot in the 
PE-10 tube. c. Connecting the PE-10 tube to the bottom of a modified PE-50 
catheter and shifting the clot into the modified PE-50 catheter. d. The clot is 




2.2.3.2.4. Thromboembolic Model 
 
 The rat was placed in a supine position, and an incision was made in 
the midline of the neck 
 The common carotid artery (CCA) was exposed under the microscope, 
so were the origin of internal carotid artery (ICA), the external carotid 
artery (ECA), the occipital artery (OA), and the superior thyroid artery 
(STA) 
 The OA and the STA were cut after coagulation 
 The bifurcation of the ICA and the pterygopalatine artery (PPA) were 
exposed 
 The origin of the PPA and the distal end of the ECA were ligated with 
4-0 silk suture 
 The proximal side of CCA and ICA with microvascular clip was 
temporally clamped, and then the distal end of the ECA near the 
ligation was cut 
 The origin of ECA was tied with a 4-0 silk suture. (This was important 
to control bleeding from cut end of the EC when the modified PE-50 
catheter was inserted.) 
 The modified PE-50 catheter was inserted about 15 mm long from the 
cut end of the ECA, then the clip was declamped at the ICA and the 
modified PE-50 catheter was inserted into the ICA (At this time, the tip 
of the catheter was placed at 2-3 mm from the origin of the MCA) 
 The clot was injected gently with a small amount of saline (rCBF was 
decreased to less than 30% of pre-ischemic baseline) (Figure 2-3) 
 After 5 min, the catheter was withdrawn from the ECA 







Figure 2-3 rCBF in the ischemic cortex after thromboembolic MCAO  
The diagram shows the time course of ischemia. Changes in cerebral blood 
flow are measured by a laser Doppler flowmeter as mentioned previously. 
Before ligations, the CBF is around 100%. As the clot is injected into the vessel, 
the ligation is started and the CBF begins to drop. In the blood flow 
obstruction period, the CBF remains a low level and consistent. In this model, 




2.2.4. Measurement of Infarct Volumes 
 
Infarct volume is one of the common indexes for assessing the extent of 
ischemic brain injury following focal cerebral ischemia. 2,3,5-
triphenyltetrazolium chloride (TTC, >95%, Sigma, US) staining is widely used in 
quantification of infarct volume in experimental stroke models. It is a rapid, 
convenient, inexpensive and reliable method after the surgery of ischemia 
and it corresponds closely with other histological methods, such as cresyl 
violet. TTC, which gives a faint yellow when dissolved in solution, is reduced 
by dehydrogenase of functioning mitochondria to yield a formazan which is 
red in color. As infarct brain tissues lacking of dehydrogenase, they remain 
unstained while normal tissues are stained red, providing visually 
identification without microscopic examination. A stock solution of 2% TTC 
was prepared by dissolving tetrazolium chloride powder (Sigma, US) in PBS. 2% 
TTC solution was stored at 4 degree for not more than three months.  
 
Rats were perfused with saline after being sacrificed. For staining brain 
sections, the rat brain was quickly removed after decapitation and all of 
overlying membranes were cleared using a fine forceps. The cerebrum was 
sectioned into eight 2-mm thick coronal slices using a brain-sectioning block 
and stained with 2% TTC solution at room temperature for 15 minutes. The 
infarct volume was measured by digital imaging software such as Image J. 
Infarct volume was expressed in mm3 or as percentage of the whole 




Figure 2-4 Measurement of infarct volumes by TTC staining 
Representative TTC-stained serial coronal brain sections and measurement of 
infarct volumes of the pMCAO. The white color is the infarctions while red is 




2.2.5. Neurological Evaluation 
 
Neurological evaluation by movement behavior was also used for the 
assessment of the extent of ischemic brain injury after cerebral ischemia. A 
set of modified Neurological Severity Scores (NSS) was used to see the 
difference after the MCAO surgery and it is shown below.[264-267] 
Neurological function was graded on a scale of 0 to 18 (normal score, 0; 
maximal deficit score, 18). NSS is a composite of motor, sensory, reflex, and 
balance tests.[268] In the severity scores of injury, 1 score point is awarded 
for the inability to perform the test or for the lack of a tested reflex; thus, the 





Table 2-1 Rat neurological evaluation by movement behavior 
 Points 
Motor tests  
      Raising rat by the tail 3 
1 Flexion of forelimb  
1 Flexion of hindlimb  
1 Head moved >10° to vertical axis within 30 s  
      Placing rat on the floor (normal=0; maximum=3)  3 
0 Normal walk  
1 Inability to walk straight  
2 Circling toward the paretic side  
3 Fall down to the paretic side  
Sensory tests  2 
1 Placing test (visual and tactile test)  
2 Proprioceptive test (deep sensation, pushing the paw 
against the table edge to stimulate limb muscles) 
 
Beam balance tests (normal=0; maximum=6)  6 
0 Balances with steady posture  
1 Grasps side of beam  
2 Hugs the beam and one limb falls down from the beam  
3 Hugs the beam and two limbs fall down from the beam, or 
spins on beam (>60 s) 
 
4 Attempts to balance on the beam but falls off (>40 s)  
5 Attempts to balance on the beam but falls off (>20 s)  
6 Falls off: No attempt to balance or hang on to the beam 
(<20 s) 
 
Reflexes absent and abnormal movements  4 
1 Pinna reflex (head shake when touching the auditory 
meatus) 
 





1 Startle reflex (motor response to a brief noise from 
snapping a clipboard paper) 
 
1 Seizures, myoclonus, myodystony  
Maximum points  18 
One point is awarded for the inability to perform the tasks or for the 
lack of a tested reflex; 13 to 18 indicates severe injury; 7 to 12, 






2.3. Brain perfusion 
 
2.3.1. Prepare Apparatus and Anesthesia 
 
Using the water bath, PBS and 2% paraformaldehyde were warmed to 37 °C. 
Two beakers filled with PBS and 2% paraformaldehyde 30 cm were placed 
above the surgical table, connected with outlet tubes and valves. The tubing 
was flushed with PBS or 2% paraformaldehyde rapidly until all air bubbles in 
the tubing were eliminated. And then the outlets were closed. Prior to 
surgery, a ketamine/xylazine mixture (up to 80 mg/kg body weight ketamine 
and 10 mg/kg body weight xylazine) was administered via intraperitoneal 
injection (27 gauge needle and 1 cc syringe). Additional administration of 
anesthetic was performed as necessary during the course of each operation 
to maintain a surgical plane of anesthesia. 
 
2.3.2. Perfusion Surgery 
 
Once the animal had reached a surgical plane of anesthesia, it was placed on 
the shallow tray and fixed by needles. Toe pinch-response method was used 
to determine depth of anesthesia. When animal was unresponsive, a 5-6 cm 
lateral incision was made through the integument and abdominal wall just 
beneath the rib cage (Figure 2-5). The liver was carefully separated from the 
diaphragm. It was followed by making a small incision in the diaphragm using 
the curved, blunt scissors. The diaphragm incision was continued along the 
entire length of the rib cage to expose the pleural cavity. Curved, blunt 
scissors was placed along one side of the ribs, carefully used to displace the 
lungs and make a cut through the rib cage up to the collarbone. A similar cut 
was made on the contralateral side. The sternum was then lifted away and 
the heart was carefully trimmed from any connecting tissue. The tip of the 
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sternum was clamped with the hemostat and the hemostat was placed over 
the head. When done properly, the thymus lifted away from the heart along 
with the sternum, providing a clear view of the heart. Then a small incision 
was made to the posterior end of the left ventricle using iris scissors. A 15-
gauge blunt- or olive-tipped perfusion needle was passed through the cut 
ventricle into the ascending aorta. The tip was visible through the wall of the 
aorta, and did not reach the aortic arch where the brachial and carotid 
arteries diverged. A hemostat was used to clamp the heart, which secured 
the needle and prevented leakage. Finally, an incision was made to the 
animal's right atrium using iris scissors to create as large an outlet as possible 
without damaging the descending aorta. At this point the animal was ready to 
be perfused. 
 
Figure 2-5 Rat perfusion surgery illustration 




100 mL PBS was injected through the needle rapidly to expel the majority of 
the blood without introducing any air bubbles. The needle was changed into 
the needle located at the end of perfusion apparatus and the angle was 
adjusted to the achievement of a maximum flow rate. Then the PBS valve was 
opened until PBS buffer was almost finished (500 ml). The fluid was running 
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clear and under observation. The clearing of the liver was an indicator of a 
good perfusion. The PBS valve was then closed and paraformaldehyde valve 
was opened until 2% paraformaldehyde (500 ml) was about to finish. Both of 
the outlet valves were closed and the needles were pulled out.  
 
2.4. Brain Dissection 
 
2.4.1. Brain Removal 
 
A surgical scissor was used to remove the head with a cut posterior from the 
ears, and to make a midline incision in the skin. Then the skin was flipped 
over the eyes to free the skull. A small incision was made on the top of the 
skull starting from the caudal part at the point of the parietal bone without 
cutting through the brain. It was followed by making a firm cut through the 
most anterior part of the skull between the eyes, which enabled to remove 
the brain more easily. Then one side of the parietal bone was tilted with 
forceps and broken off. The same was done for the other side. After that the 
frontal bone remained, a small incision was made to enable tilting and 
breaking off this bone plate without pulling the meninges that were 
surrounding the brain and that were between the brain and the skull. When 
the brain was freed from meninges, the forceps was sliced under anterior 
part of the brain (olfactory bulb) and the brain was tilted gently upward. Then 
the forceps was sliced further down to break the optic nerves and other 
cranial nerves and the brain was gently lifted out of the skull. Finally the brain 




The pons was cut through by closing the forceps around the tissue. When the 
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majority of the white tissue was removed, the brain was turned around with 
the ventral side facing the plate. Then the small forceps were place between 
the cortical lobes and the cerebellum and the cerebellum was snapped off 
from the colliculus inferior. Then possible remaining parts of the pons were 
removed. It was followed by turning the brain around with the dorsal side 
facing the plate and pulling the midbrain part off. Then the brain was cut from 
the midline into two halves. The interior was scratched off from bottom 
cerebrum. The first region snapped off was hypothalamus and thalamus. 
Then forceps were sliced from upper middle to the bottom side to separate 
hippocampus. Finally the fan shape striatum was scratched off and the left 
part was cortex. 
 
2.5. Primary Astrocyte Culture 
 
Mostly the procedure was adapted from a dissection and tissue culture 
manual of the nervous system.[271]  
 
2.5.1. Brain Dissection  
 
Two or three 1-3 day old neonatal SD rat pups were sacrificed in the ice and 
soaked in 70% ethanol for sterilization purpose. Using microdissecting scissors, 
the skin was opened at the midline of the head and cut from the base of the 
skull to the mid-eye area. After folding back the skin flaps with the scissors, 
the skull was cut at the midline fissure, without touching the brain tissue. The 
raised skull cap was removed with the curved forceps, applying slight 
pressure. The brain was then released from the skull cavity by running a 
microspatula underneath and along the length of the brain from the olfactory 
lobes to the beginning of the spinal cord. After gently transferring the brain to 
a 75 mm Petri dish, it was rinsed with a squirt of modified DMEM/F12 culture 
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medium, containing 10% FBS, 1% glutamine and gentamicin antibiotic, from a 
syringe to remove the adhering blood and moisten the tissue. An identical 
procedure was performed for the second and third brain. The brains were 
then moved to a second petri dish and placed in a tissue culture hood. Using 
micro-dissecting forceps, each brain was transferred to the inverted lid of a 35 
mm Petri dish that was resting on a pad of sterile gauze. While steadying the 
brain with the forceps, the cerebrum was separated from the cerebellum and 
brain stem, and the cerebral hemispheres were separated from each other by 
gently teasing along the midline fissure with the sharp edge of a second 
forceps. The cortex (grey matter containing the cell bodies) was deflected and 
peeled away, leaving behind the white matter. The meninges were gently 
peeled from the individual cortical lobes that were immediately placed into a 
fresh 75 mm Petri dish containing modified DMEM/F12 culture media.  
 
2.5.2. Tissue Digestion  
 
Cortices were dissociated into a cell suspension using mechanical digestion. 
After digestion, any remaining undigested tissue was plated as an explant in 
modified DMEM/F12 culture medium. Cells were plated in 75 cm2 tissue 
culture flasks at a concentration of 15 x 106 cells in 11 ml of medium. 
Incubating the flasks at 37°C in a moist 5% CO2, 95% air atmosphere for 48-72 
hours before moving, allowed the cells sufficient time to adhere and begin 
multiplying. The medium was changed at this time and every 48-72 hours 
until the cells were ready to be used for culture on slides.  
 
2.5.3. Culture purification  
 
After incubating the primary cultures for 7-9 days, the medium was changed 
completely (11 ml), and the caps were tightened. Flasks were wrapped in 
67 
 
plastic, placed on a shaker platform in a horizontal position with the medium 
covering the cells, and were shaken at 350 rpm for 6 hours at 35°C to 
separate the oligodendrocytes from the astrocytes. The flasks were changed 
with 10 ml of medium and replaced on the shaker for 18 hours. After 
removing the flasks, the contents were aseptically poured into a new 75 cm2 
flask, and placed in the incubator. The shaken flasks were again changed with 
10 ml of fresh medium and the shaking process was repeated for an 
additional 24 hours. Contents were then aseptically poured into a new 75 cm2 
flask, and placed in the incubator. When confluent, cells were passed from 
the flasks into sterile Petri dishes or plates.  
 
2.6. Oxygen-Glucose Deprivation 
 
When 70-80% confluent, cells were pre-treated with serum-free medium and 
bubbled with 95% N2 and 5% CO2 30 min prior to oxygen-glucose deprivation 
(OGD). Then the medium was changed to DMEM without glucose and 
without glutamine. Hypoxia was induced by placing the cells in a chamber 
(Billups-Rothenberg) and perfusing the chamber with 95% N2, 5% CO2 for 10 
minutes. The chamber was then sealed and kept at 37°C for 3h, 8h and 24h. 
At the end of each time point, the medium was changed to serum-free 
DMEM and the cells were re-oxygenated in the incubator at 37°C for 
respective different time till 24h. After 24h, cell survival was determined 




2.7.1. Fluorescent Staining 
 
The localizations of 3MST were examined in rat tissues using fluorescent 
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staining. pMCAO or sham-operated brain were removed from rats 
transcardially perfused with ringer solution and 2% paraformaldehyde and 
immersion-ﬁxed in 2% paraformaldehyde for 4 h, dehydrated in 15% sucrose 
overnight, embedded in OCT compound (Sakura Finetek, Torrance, CA, USA), 
cryosectioned to 30 µm-thick sections, and thaw mounted on gelatin-coated 
slides. Non-specific binding was blocked by incubating the section in 5% goat 
serum for 1h. This was followed by overnight incubation with 3MST antibody 
(1:200, Sigma-Aldrich) and one of the following three antibodies: anti-NeuN 
(1:200, Millipore, MAB377), a postmitotic neuronal nuclei marker; anti-glial 
ﬁbrillary acidic protein (GFAP, 1:200, Sigma-Aldrich), a speciﬁc type of 
fibrillary protein used as astrocyte marker; and anti-OX-42 (CD11b, 1:200, 
AbD Serotec), a monoclonal antibody recognizing the C3bi complement 
receptor expressed by microglial cells. This was followed by incubation of FITC 
conjugated goat anti-rabbit IgG used against 3MST antibody and Cy3 
conjugated goat anti-mouse IgG used against anti-NeuN, anti-GFAP or anti-OX 
42 for 1h for ﬂuorescent labelling. Sections were then incubated in 4’,6-
Diamidino-2-phenylindole dihydrochloride (DAPI, Sigma-Aldrich, 0.5 μg/ml in 
PBS) for 5 minutes, mounted and observed under a confocal microscope 
(Olympus, Tokyo, Japan). 
 
2.7.2. DAB Staining 
 
The localizations of 3MST were also examined in rat tissues using DAB (3,3′-
Diaminobenzidine, tetrahydrochloride) staining. The brain were removed 
from rats transcardially perfused with ringer solution and 2% 
paraformaldehyde and immersion-ﬁxed in 2% paraformaldehyde for 4 h, 
dehydrated in 15% sucrose overnight, embedded in OCT compound (Sakura 
Finetek, Torrance, CA, USA), cryosectioned to 30 µm-thick sections, and thaw 
mounted on gelatin-coated slides. Non-specific binding was blocked by 
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incubating the section in 5% goat serum for 1h. This was followed by 
overnight incubation with 3MST antibody (1:200, Sigma-Aldrich). Then it was 
the incubation of goat anti-rabbit IgG used against 3MST antibody for 1h. 
After washed for three times, the slides were incubated with ABC Kit [Vector 
Labs, VECTASTAIN Elite (Rabbit IgG)] for 1h. Then DAB stock solution was 
diluted to 1:10 in PBS to a final working concentration of 1 mg/mL from DAB 
stock solution that had been stored frozen. It was followed by adding H2O2 to 
the DAB working solution to a final concentration of 0.03% (1:1000 dilution 
from the 30% solution provided). After that about 250 µL of DAB/H2O2 
working solution was immediately applied to the surface of the slides. And 
the slides were incubated horizontally in DAB for 10 minutes, washed for 
more than four times, rinsed in 0.1M Acetate buffer (pH 4.8), counterstained 
with  0.5% Methyl Green and dehydrated in 100% ethanol.  And finally the 
slides were cleared and mounted. Then the section could be visually 
inspected at low magnification under a microscope against a white 
background to assess the degree of color development.  
 
2.8. Western Blot Analysis 
 
Brain tissues were homogenized in cold lysis buffer [10 mM HEPES, pH 7.9 
with 1.5 mM MgCl2 and 10 mM KCl, containing protease inhibitor cocktails 
(Roche Diagnostics GmbH, Mannheim, Germany)]. The lysates were 
centrifuged for 10 min at 14000×g. The cytoplasmic fractions containing equal 
amounts of protein, as determined by the Nano-Drop method (Thermo 
Scientific), were separated by 10% SDS/PAGE and transferred onto a 
nitrocellulose membrane (Amersham Biosciences, Buckinghamshire, UK). 
After incubating in 10% milk at room temperature in TBST buffer (10 mM Tris-
HCl, 120 mM NaCl, 0.1% Tween-20, pH 7.4) for 1 h, the membranes were 
incubated with antibodies against 3MST (Sigma-Aldrich) at 4°C overnight, and 
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then incubated with 1:1000 dilutions of HRP-conjugated anti-rabbit IgG at 
room temperature for 1h. The visualization was detected using a high quality 
fluorescent camera (UVItec Cambridge). The density of the bands on the 
membranes was quantified by densitometry analysis of the scanned blots 
using UVIband software. All protein levels were normalized to the 
corresponding β-actin bands (Sigma-Aldrich). For Western blotting, the 
contralateral side of the pMCAO brain was used as control instead of sham 
animals in order to reduce the number of animals used to a minimum as 
preliminary data showed no significant difference between the contralateral 
side and sham-control. 
 
2.9. H2S-Producing Enzyme Assay 
 
2.9.1. 3MST Assay 
 
All incubations were performed in reaction tubes fitted with air-tight serum 
caps and plastic center wells. The center well contained a folded 2 cm x 2.5 
cm filter paper (Whatman No.1) wetted with 0.5 ml of 1% (w/v) zinc acetate 
in 12% NaOH for trapping evolved H2S. Brain homogenate (300 μl, 14.3% w/v) 
in 50 mM potassium phosphate buffer (pH6.8) was mixed with 3-MP (2 mM, 
sodium salt, Sigma-Aldrich) and  2-mercaptoethnol (10 mM, Sigma-Aldrich) 
with or without  2-ketobutyric acid (40 mM), an uncompetitive inhibitor of 
3MST,[78, 272] in the reaction tube in an ice bath. Total volume was 0.4 ml. 
The reaction tube was then flushed with N2 for 20s and then capped. The 
reaction was initiated by transferring the tube to a 37°C shaking bath. After 
incubating for 90 min, the reaction was stopped by injecting trichloroacetic 
acid (0.5 ml, 50% w/v) through the serum cap. After 1h incubation at 37°C to 
allow complete trapping of H2S, the center well was taken out. N,N-Dimethyl-
p-phenylenediamine sulphate in 7.2M HCl (0.5 ml, 20 mM) and FeCl3 in 1.2M 
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HCl (0.5 ml, 30 mM) were added and left in the dark at room temperature for 
20 min. Finally the absorbance at 670 nm was determined with a 
spectrophotometer (Epoch, BioTek). Blanks were obtained by replacing brain 
homogenate with buffer. Calibration curve was obtained using NaHS (0-1 
mM). 
 
2.9.2. CBS Assay 
 
All incubations were performed in reaction tubes fitted with air-tight serum 
caps and plastic center wells. The center well contained a folded 2 cm x 2.5 
cm filter paper (Whatman No.1) wetted with 0.5 ml of 1% (w/v) zinc acetate 
in 12% NaOH for trapping evolved H2S. Brain homogenate (300 μl, 50% w/v) 
in 50 mM potassium phosphate buffer (pH6.8) was mixed with 10 mM 
cysteine, 10 mM homocysteine and 2 mM pyridoxal 5'-phosphate with or 
without AOAA (200 µM) in the reaction tube in an ice bath. Total volume was 
0.4 ml. The reaction tube was then flushed with N2 for 20s and then capped. 
The reaction was initiated by transferring the tube to a 37°C shaking bath. 
After incubating for 90 min, the reaction was stopped by injecting 
trichloroacetic acid (0.5 ml, 50% w/v) through the serum cap. After 1h 
incubation at 37°C to allow complete trapping of H2S, the center well was 
taken out. N,N-Dimethyl-p-phenylenediamine sulphate in 7.2M HCl (0.5 ml, 
20 mM) and FeCl3 in 1.2M HCl (0.5 ml, 30 mM) were added and left in the 
dark at room temperature for 20min. Finally the absorbance at 670 nm was 
determined with a spectrophotometer (Epoch, BioTek). Blanks were obtained 
by replacing brain homogenate with buffer. Calibration curve was obtained 
using NaHS (0-1 mM). 
 




We used a reactive disulfide-containing probe (compound 1) to detect the 
concentration of H2S. This compound was prepared from thiosalicylic acid 2 in 
two steps. The fluorescence property of this probe was tested in aqueous PBS 
solution (pH 7.4). Compound 1 (fluorescence quantum yield: Φ=0.003) 
adopted a closed lactone conformation and exhibited no absorption features 
in the visible region. In these experiments, NaHS was used as the equivalent 
of H2S to make the standard curve. It is known that in aqueous state under 
the physiological pH of 7.4, the major form of H2S exists as HS−; the ratio of 
HS−/H2S is approximately 3:1.9 
 
2.10.1. Synthesis of Probe 
 
To a solution of compound 31 (3.3 g, 15 mmol) in chloroform (80 ml) was 
added 2-mercaptobenzoic acid 2 (2.31 g, 15 mmol), the mixture was stirred 
for 12 hours. Then, the solvent was removed under reduced pressure to 
produce a yellow solid which is compound 4 (~5.5g) (Figure 2-6). This product 
was used directly in next reaction without further purification. 
 
 
Figure 2-6 Synthesis of the probe 
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Compound 1 is synthesized from compound 2.  
 
To a mixture of compounds 4 (262 mg, 1.0 mmol), compounds 5 (346 mg, 1.0 
mmol), EDC (192 mg, 1.0 mmol) and DMAP (12.2 mg, 0.1 mmol) were added 
CH2Cl2 (25 mL) at room temperature. The mixture was stirred for 12 hours. 
Then solvent was evaporated under reduced pressure and resulted residue 
was subjected to flash column chromatography for purification. Compound 1 
was obtained as a light yellow solid (210 mg, 36% yield for two steps). 1H 
NMR (300 MHz, CDCl3) δ 3.85 (s, 3H), 6.62-6.74 (m, 2 H), 6.80 (m, 1H), 6.87-
6.98 (m, 2H), 7.10 (m, 1 H), 7.20 (m, 1 H), 7.25-7.27 (m, 1 H), 7.35 (m, 1 H), 
7.52-7.72 (m, 5 H), 8.02 (m, 2 H), 8.30 (m, 1 H), 8.48 (m, 1 H). 13C NMR (75 
MHz, CDCl3) δ 169.3, 164.3, 161.4, 158.8, 153.0, 152.2, 151.9, 151.7, 149.6, 
141.7, 137.3, 135.2, 134.0, 132.1, 129.9, 129.2, 129.0, 126.4, 126.1, 125.9, 
125.8, 125.1, 124.0, 121.0, 119.7, 117.5, 117.1, 112.0, 110.8, 110.5, 100.8, 
82.4, 55.6; MS (ESI+) m/z 592.0 (M+H+); IR 3647.8, 1716.1, 1652.0, 1557.9, 
1540.2, 1506.3, 1456.3, 1418.1. 
 
2.10.2. Reaction of H2S Probe with H2S 
 
To the solution of 1 (59.1 mg, 0.1 mmol) in CH3CN (2 ml) and PBS buffer (18 
ml, 1 mM, PH = 7.4) was added NaHS (5.6 mg, 0.1 mmol). The mixture was 
stirred for 1 hour at room temperature. The color of solution turned to dark 
green. Ethyl acetate (50 ml) was added into the solution to extract the 
product. The organic layers were separated, dried by MgSO4, and 
concentrated in vacuo. Purification by flash column chromatography afforded 
compound 73 as light yellow solid (14.0 mg, 83% yield) (Figure 2-7). The 
formation of 6 was confirmed by HPLC and UV/vis studies in comparison to 





Figure 2-7 Reaction of the probe with H2S 
The probe reacts with H2S and the fluorescent signals are released.  
 
2.10.3. Experimental Procedure 
 
2.10.3.1. Determination of Wavelength for H2S 
Detection 
 
To demonstrate the efficiency of the probes in the measurement of H2S 
concentration, varying concentrations of NaHS were added to the solutions to 
obtain a standard curve of fluorescence intensity to H2S concentration. The 
concentration of the probe was maintained at 100 μM while the 
concentrations of NaHS varied from 0 to 50 μM. All of the signals were 
detected by a fluorescence spectrophotometer (Evolution 300 Cary Eclipse, 
Agilent Technologies). 
 
2.10.3.2. H2S Standard Curve 
 
1 ml PBS was added into each well of empty 12-well plates, following by 60 µl 
DMSO, 40 µl probe and 10 µl Cetyl trimethylammonium bromide (CTAB). 
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After that the wells were added by various concentrations of NaHS (0.2 µl-100 
µl). Then the plates were incubated for 30mins and afterwards the signals 
were detected under a fluorescence plate reader.  
 
2.10.3.3. H2S in the Cells 
 
Primary astrocytes were seeded into 12-well plates and incubated in 37°C 
with or without 10 µM AOAA and 1 mM 2-ketobutyric acid. It was followed by 
the removal of media and wash by PBS once. Then 1 ml PBS was added into 
each well, following by 60 µl DMSO, 40 µl probe and 10 µl Cetyl 
trimethylammonium bromide (CTAB). Then the cells were incubated for 
30mins and afterwards the signals were detected under a fluorescence plate 
reader. For the detection of cellular signaling expression, 
immunohistochemistry pictures were taken under a fluorescent microscope 
after DAPI and fluoro gels were added in.  
 
2.11. Statistical Analysis 
 
All statistical analyses of the data were performed by using Excel 2013 
(Microsoft, Redmond, WA) and SPSS 20 (IBM, Armonk, NY). Differences 
between two groups were analyzed with Student’s t test. Differences 
between three or more groups were analyzed with one-way analysis of 
variance (ANOVA). Post hoc multiple comparisons were made by using the 
Bonferroni test. Values are expressed as mean ± SE. P values <0.05 were 





3.1. H2S-Producing Enzyme Activities 
 
3.1.1. H2S Concentration Standard Curve 
 
The calibration curve was obtained according to the linear relationship 
between different H2S concentrations (1000 μM, 250 μM, 100 μM, 50 μM, 25 
μM, 12.5 μM, 0 μM) and the absorbance at 670 nm (Table 3-1). The 
absorbance is dependent from amount of H2S released from NaHS, so the 
equation can be used as H2S production scale for tissue homogenates under 
the same condition (Figure 3-1).   
 
Table 3-1 H2S concentration determination 












Figure 3-1 H2S concentration standard curve 
All the reaction was in 50 mM potassium phosphate buffer at 37°C. NaHS was 
used as H2S donor and the concentrations are 1000 μM, 250 μM, 100 μM, 50 
μM, 25 μM, 12.5 μM and blank. The absorbance was determined at 670 nm.  
  




















3.1.2. 3MST Activities in the Brain 
 
3MST activities were examined in all six brain regions (cortex, striatum, 
hippocampus, hypothalamus + thalamus, midbrain and cerebellum) as shown 
in Figure 3-2. There appeared to be no significant differential distribution with 
all regions exhibiting mean activities in the range of about 21 to 26 µmol/g 
tissue/h. In the presence of 40 mM 2-ketobutyric acid, 3MST activities were 
almost completely inhibited showing that no other enzymes contributed to 
the production of H2S under the assay conditions used. The percentage of 
inhibition by 2-ketobutyric acid was shown in Figure 3-3.  
 
Figure 3-2 3MST activities in six different regions of the rat brain 
3MST activities in six different regions of the rat brain, which are cortex, 
striatum, hippocampus, hypothalamus + thalamus, midbrain and cerebellum. 
3MST activities were measured biochemically in tissue homogenates in the 
absence (solid bars) and presence of 2-ketobutyric acid (open bars) as 





































Figure 3-3 Percentage of the inhibition by 2-ketobutyric acid 
The concentration 2-ketobutyric acid is 40 mM, 3MST inhibition rates were 
measured for cortex, striatum, hippocampus, hypothalamus + thalamus, 
midbrain and cerebellum as described in materials and methods. 
  










3.1.3. CBS Activities in the Brain 
 
CBS activities were examined in all six brain regions (cortex, striatum, 
hippocampus, hypothalamus + thalamus, midbrain and cerebellum) as shown 
in Figure 3-4. The activities of CBS appeared to be no significant differential 
distribution with cortex, hippocampus and hypothalamus + thalamus in the 
range of about 2 to 3 µmol/g tissue/h. But the activity of CBS in striatum (1.97 
± 0.07) was significantly lower than any other regions while the activity of CBS 
in midbrain (3.64 ± 0.12) was significantly higher than any other regions 
except cerebellum. However the activity of CBS in cerebellum (8.12 ± 0.20) 
was much higher than any others to a large extent, indicating that CBS in 
cerebellum was highly expressed. After inhibition by 200 μM AOAA (100 
times more concentrated than IC50 of AOAA which is around 2 μM to make 
sure the inhibition was complete), the suppress of H2S production was solid 
for cortex, striatum, hippocampus, hypothalamus + thalamus (more than 
80%). However the inhibition for CBS in midbrain and cerebellum was not 
thorough enough (less than 60%), indicating that there were some other 
enzymes except CBS catalyzing H2S genesis in midbrain and cerebellum 
according to the data showing percentages of the inhibition by concentrated 





Figure 3-4 CBS activities in six different regions of the rat brain 
CBS activities in six different regions of the rat brain. CBS activities were 
measured biochemically in tissue homogenates in the absence (solid bars) 
and presence of AOAA (open bars) as described in materials and methods; 










































Figure 3-5 Percentage of the inhibition by AOAA 
The concentration AOAA is 200 μM, CBS inhibition rates were measured for 
cortex, striatum, hippocampus, hypothalamus + thalamus, midbrain and 
cerebellum as described in materials and methods. 
  










3.2. 3MST Regional and Cellular Localization 
 
The expression of 3MST in brain cells was demonstrated using fluorescent 
immunohistochemical staining. Figure 3-6 and Figure 3-7 showed 3MST 
immunoreactivity in the cortex and striatum, respectively. By double 
immunostaining, 3MST was demonstrated to localize in astrocytes as it 
colocalized with GFAP immunoreactivities. In contrast, 3MST 
immunoreactivity did not colocalize with NeuN or OX42, indicating that it was 
not expressed in neurons or microglia. At the subcellular level, 3MST 
immunoreactivity appeared to be cytoplasmic and was present in both the 
processes and cell soma of the astrocytes. High magnification 
photomicrograph in striatum was shown in Figure 3-8. A perfect overlap 





Figure 3-6 Cellular localization of 3MST using dual-fluorescent 
immunohistochemical labelling on rat cortical sections 
(a) 3MST immunoreactivity (green) does not colocalize with NeuN-
immunoreactive neurons (red). (b) 3MST immunoreactivity colocalizes with 
GFAP-immunoreactive astrocytes (red). (c) 3MST does not colocalize with 
OX42-immunoreactive mciroglial cells (red). Scale bar = 50 µm. All sections 





Figure 3-7 Cellular localization of 3MST using dual-fluorescent 
immunohistochemical labelling on rat striatal sections 
(a) 3MST immunoreactivity (green) does not colocalize with NeuN-
immunoreactive astrocytes (red). (b) 3MST immunoreactivity (green) 
colocalizes with GFAP-immunoreactive neurons (red). (c) 3MST (green) does 
not colocalize with OX42-immunoreactive mciroglial cells (red). Scale bar = 50 





Figure 3-8 Cellular localization of 3MST using dual-fluorescent 
immunohistochemical labelling on rat striatal sections 
High magnification photomicrograph showing an astrocyte stained positive 





The expression of 3MST in brain cells was also demonstrated using DAB 
immunohistochemical staining. Figure 3-9 showed 3MST immunoreactivity in 
the cortex and striatum, respectively. It is clearly seen that there was 3MST 
expression in both cortex and striatum. And the cellular morphology was 
consistent with fluorescent immunohistochemical staining. So it can be 
confirmed that 3MST is localized to astrocytes. At the subcellular level, 3MST 
immunoreactivity appeared to be cytoplasmic and was present in both the 
processes and cell soma of the astrocytes. 
 
Figure 3-9 Cellular localization of 3MST using DAB immunohistochemical 
labelling on rat cerebral sections 
The left panel is the expression of 3MST in cortex, and the right panel is the 




3.2.1. 3MST Expression in Mice 
 
The expression of 3MST in layer V of the mouse neocortical areas was 
demonstrated using fluorescent immunohistochemical staining. Figure 3-10 
showed that by double immunostaining, 3MST was demonstrated to localize 
in astrocytes as it colocalized with GFAP immunoreactivities, which is similar 
to 3MST localization in rats. In contrast, 3MST immunoreactivity did not 
colocalize with NeuN, indicating that it was not expressed in neurons in cortex. 
Figure 3-11 showed 3MST expression in the cerebellum, and 3MST had no 
colocalization with NeuN immunoreactivities in mouse cerebellum as well. At 
the subcellular level, similarly to rats, 3MST immunoreactivity appeared to be 






Figure 3-10 Cellular localization of 3MST using dual-fluorescent 
immunohistochemical labelling on layer V of mouse neocortical areas 
(a) 3MST immunoreactivity (green) colocalizes with GFAP-immunoreactive 
astrocytes (red). (b) 3MST immunoreactivity (green) does not colocalize with 
NeuN-immunoreactive neurons (red). Scale bar = 50 µm. All sections were 
observed with an Olympus confocal fluorescent microscope. 
 
 
Figure 3-11 Cellular localization of 3MST using dual-fluorescent 
immunohistochemical labelling on mouse cerebellum  
3MST immunoreactivity (green) does not colocalize with NeuN-
immunoreactive neurons (red). Scale bar = 50 µm. All sections were observed 




Figure 3-12a showed 3MST immunoreactivity in mouse corpus callosum. By 
double immunostaining, 3MST was demonstrated to localize in astrocytes as 
it colocalized with GFAP immunoreactivities. Figure 3-12b and Figure 3-12c 
showed the colocalization of 3MST immunoreactivity in mouse striatum with 
GFAP and NeuN immunoreactivities, respectively. And similar to the other 
regions of the mouse brain, 3MST colocalized with GFAP rather than NeuN, 





Figure 3-12 Cellular localization of 3MST using dual-fluorescent 
immunohistochemical labelling on mouse corpus callosum and striatum  
(a) 3MST immunoreactivity (green) colocalizes with GFAP-immunoreactive 
astrocytes (red) in the corpus callosum. (b) 3MST immunoreactivity (green) 
colocalizes with GFAP-immunoreactive astrocytes (red) in the striatum. (c) 
3MST immunoreactivity (green) does not colocalize with NeuN-
immunoreactive neurons (red) in the striatum. Scale bar = 50 µm. All sections 




3.3. 3MST Expression after pMCAO 
 
The model selection for pMCAO was among three most popular ones which 
were permanent transcranial model, filament model and thromboembolic 
model for ischemic research. Thromboembolic Model had the highest 
pathophysiological relevance and severity score (14.4 ± 4.2) but the 
consistence was not good (Figure 3-13). Also the excessive failure caused by 
spontaneous recanalization and high mortality rate caused by hemorrhage 
were the other two main reasons not to use the method. The success rate for 
thromboembolic model was just around 50%. Filament model was more 
reproducible and had a much higher success rate which was nearly 80%, but 
the severity (8.2 ± 2.3) of the model was not enough for latter ischemic 
experiments without recovery especially for those in long terms. Finally we 
chose the more consistent permanent transcranial model with a reasonable 
success rate (70%) and a high neurological severity score (14.2 ± 2.6). 
 
Figure 3-13 Neurological evaluation after pMCAO by movement behavior 
Neurological severity score was tested at 24h after pMCAO for all of the 


































3.3.1. 3MST Expression in Cortex 
 
3.3.1.1. 3MST Expression at Various Time Points in 
Cortex 
 
When the expression of 3MST was investigated in the cortex after pMCAO by 
Western blotting, the infarct areas involved the cortex, striatum, corpus 
callosum and hippocampus as shown in Figure 3-14. It was found that 3MST 
was significantly down-regulated by about 40-50% at 72h in the cortex. Figure 
3-14 showed TTC-stained sections (2 mm) of a rat forebrain after pMCAO and 
the infarct regions were not stained by TTC thus appear white. 
Photomicrographs presented from Figures 3-16 to Figure 3-23 were taken 
from the peri-infarct areas at the level of +1 mm from bregma as indicated. a: 





Figure 3-14 TTC-stained sections of a rat forebrain after pMCAO 
The infarct regions are not stained by TTC thus appear white. 
Photomicrographs presented Figures 3-16 to Figure 3-23 are taken from the 
peri-infarct areas at the level of +1 mm from bregma as indicated. a: cortex; b: 







Figure 3-15 3MST expression in the ipsilateral cortex at various time points 
after pMCAO 
Representative western blot bands are shown in the top panel. N=4. * p<0.05 



































3.3.1.2. 3MST Expression at 24h after pMCAO in 
Cortex 
 
At 24h after pMCAO, it was observed that the tissue in the infarct area was 
damaged. Almost all of the cells were dead and no positive 3MST staining 
could be taken by the camera (Figure 3-16). In that case all of the pictures 
later showing the ischemic brain were from peri-infarct areas.  
 
Figure 3-16 3MST expression in infarct area in the ipsilateral cortex at 24h 
after pMCAO 
3MST immunoreactivity (green) in infarct area in the ipsilateral cortex at 24h 
after pMCAO is shown in the left panel.  GFAP-immunoreactive astrocytes 
(red) are shown in the middle panel. Right panel is the merge the previous 
two and DAPI. Scale bar = 100 μm. 
 
Immunostaining results are generally consistent with the Western blot 
analyses as shown in Figure 3-15. At 24h after pMCAO, it was observed that 
both 3MST and GFAP immunoreactivities were much reduced in the cortex 
(Figure 3-17), indicating that 3MST expression was suppressed despite 
astrocyte proliferation. And the cellular localization of 3MST was still in 






Figure 3-17 3MST expression in the ipsilateral cortex at 24h after pMCAO 
3MST immunoreactivity (green) and GFAP-immunoreactive astrocytes (red) in 
the ipsilateral cortex at 24h after pMCAO (a) and sham-operated cortex (b). 
Merged photomicrographs (right panel) show co-localization of 3MST and 





3.3.1.3. 3MST Expression at 72h after pMCAO in 
Cortex 
 
At 72h after pMCAO, it was observed that both 3MST and GFAP 
immunoreactivities were further reduced in the cortex compared to 24h after 
pMCAO (Figure 3-18). At 72h, GFAP immunoreactivity was quite comparable 
to control, reflecting a significant level of gliosis. However, 3MST 
immunoreactivity remained low at this time point indicating that 3MST 
expression continued to be suppressed despite astrocyte proliferation. 
 
Figure 3-18 3MST expression in the ipsilateral cortex at 72h after pMCAO 
3MST immunoreactivity (green) and GFAP-immunoreactive astrocytes (red) in 
the ipsilateral cortex at 72h after pMCAO (a) and sham-operated cortex (b). 
Merged photomicrographs (right panel) show co-localization of 3MST and 





3.3.2. 3MST Expression in Striatum 
 
3.3.2.1. 3MST Expression at Various Time Points in 
Striatum 
 
The expression of 3MST was investigated in the striatum after pMCAO by 
Western blotting. It was found that 3MST was significantly down-regulated by 





Figure 3-19 3MST expression in the ipsilateral striatum at various time 
points after pMCAO 
Representative western blot bands are shown in the top panel. N=4. * p<0.05 


































3.3.2.2. 3MST Expression at 24h after pMCAO in 
Striatum 
 
Immunostaining results are generally consistent with the Western blot 
analyses shown in Figure 3-20. At 24h after pMCAO, it was observed that 
both 3MST and GFAP immunoreactivities were much reduced in the striatum, 
indicating that 3MST expression was suppressed despite astrocyte 
proliferation. And the cellular localization of 3MST was still in astrocytes in 
striatum, which remained unchanged despite of the damage caused by 
pMCAO.  
 
Figure 3-20 3MST expression in the ipsilateral striatum at 24h after pMCAO 
3MST immunoreactivity (green) and GFAP-immunoreactive astrocytes (red) in 
the ipsilateral striatum at 24h after pMCAO (a) and sham-operated striatum 
(b). Merged photomicrographs (right panel) show co-localization of 3MST and 





3.3.2.3. 3MST Expression at 72h after pMCAO in 
Striatum 
 
At 72h after pMCAO, it was observed that 3MST immunoreactivity was much 
reduced in striatum (Figure 3-21). GFAP immunoreactivity was quite 
comparable to control, also reflecting a significant level of gliosis. And similar 
to cortex, 3MST immunoreactivity in striatum became even lower at 72h 
indicating that 3MST expression continued to be suppressed despite 
astrocyte proliferation.    
 
Figure 3-21 3MST expression in the ipsilateral striatum at 72h after pMCAO 
3MST immunoreactivity (green) and GFAP-immunoreactive astrocytes (red) in 
the ipsilateral striatum at 72h after pMCAO (a) and sham-operated striatum 
(b). Merged photomicrographs (right panel) show co-localization of 3MST and 





3.3.3. 3MST Expression in Corpus Callosum 
 
3.3.3.1. 3MST Expression at 24h after pMCAO in 
Corpus Callosum 
 
In contrast to the cortex and striatum, immunostaining results showed that 
3MST expression did not appear to be affected in the corpus callosum at 24h 
after pMCAO (Figure 3-22).  And also the influence on GFAP was not apparent. 
Therefore, it appears that the suppression of 3MST expression is not a general 
phenomenon occurring in all peri-infarct regions following pMCAO. 
 
Figure 3-22 3MST expression in the ipsilateral corpus callosum at 24h after 
pMCAO 
3MST immunoreactivity (green) and GFAP-immunoreactive astrocytes (red) in 
the ipsilateral corpus callosum at 24h after pMCAO (a) and sham-operated 
corpus callosum (b). Merged photomicrographs (right panel) show co-




3.3.3.2. 3MST Expression at 72h after pMCAO in 
Corpus Callosum 
 
Similar to 24h after pMCAO, immunostaining results showed that 3MST 
expression did not appear to be affected in the corpus callosum at 72h after 
pMCAO (Figure 3-23). And also the influence on GFAP was not apparent as 
well. This is consistent with the idea that the suppression of 3MST expression 
is a consequence of the induced stroke as the corpus callosum lies outside 
the infracted area following pMCAO. However, the possibility of a change in 
3MST expression in this region at a later time point may not be ruled out. 
 
Figure 3-23 3MST expression in the ipsilateral corpus callosum at 72h after 
pMCAO 
3MST immunoreactivity (green) and GFAP-immunoreactive astrocytes (red) in 
the ipsilateral corpus callosum at 72h after pMCAO (a) and sham-operated 
corpus callosum (b). Merged photomicrographs (right panel) show co-





3.4. 3MST Expression in Cerebellum and 
Midbrain 
 
3MST expression in rat cerebellum was also investigated in a preliminary level. 
The cells near molecular layer showed strong 3MST activity (Figure 3-24). 
However no double staining data supported the cellular localization of the 
signals. But according to the morphology and location, there is a higher 
likelihood that they were granule cells. If so, it might be a clue that H2S, the 
product of 3MST, plays a role as neuromodulator in cerebellum although the 
majority of 3MST in the cerebrum is in astrocytes (Figure 3-6 and Figure 3-7).  
 
Figure 3-24 Cellular localization of 3MST using fluorescent 
immunohistochemical labelling on normal cerebellar sections 
The left panel (green) is the staining with 3MST and the right panel (blue) is 
the staining with DAPI. All sections were observed with an Olympus confocal 





3MST expression in rat cerebellum was confirmed by DAB staining as well 
(Figure 3-25). The positive staining was in the cells near molecular layer. The 
localization was more than one layer, so Purkinje cell was excluded. In a word, 
double staining between 3MST and granule cells is still necessary to confirm 
the cellular localization of 3MST in cerebellum in the future.  
 
Figure 3-25 Cellular localization of 3MST using DAB immunohistochemical 
labelling on normal cerebellar sections 
The middle panel is the magnified squared area of the left panel. The right 
panel is the magnified squared area of the middle panel. In the cerebellum, 
3MST staining is seen in the white matter, molecular layer, Purkinje cell layer 





3MST expression in rat midbrain was investigated in a preliminary level as 
well. 3MST activity in midbrain is shown in Figure 3-26. However no double 
staining data support the cellular localization of the signals.  
 
Figure 3-26 Cellular localization of 3MST using fluorescent 
immunohistochemical labelling on midbrain sections 
Cellular localization of 3MST using fluorescent immunohistochemical labelling 
on normal rat midbrain sections under 20x magnifications. The left panel 
(green) is the staining with 3MST and the right panel (blue) is the merge of 
3MST and DAPI. All sections were observed with an Olympus confocal 




3.5. 3MST Expression in Primary Astrocytes 
under OGD 
 
The expression of 3MST in primary astrocytes under OGD condition was 
investigated by western blotting. It was found that 3MST was significantly 
down-regulated by about 40% at 24h and 50% at 48h compared to control 
(Figure 3-27). Immunostaining results were generally consistent with the 
western blot analyses as shown in Figure 3-28.  3MST expression decreased 
as OGD time increased. Additionally these figures clearly showed that 3MST 
immunoreactivity remained colocalizing with astrocytes in primary astrocytes 






Figure 3-27 3MST expression in primary astrocytes at various time points of 
OGD 
Representative western blot bands are shown in the top panel. In the bottom 
panel, 3MST activities at 1h, 3h, 8h, 24h and 48h of OGD time points were 
indicated as solid bars while and 3MST activities of control were indicated as 





































Figure 3-28 3MST expression using fluorescent immunohistochemical 
labelling on primary astrocytes in OGD conditions 
3MST immunoreactivity (green) in 5min, 1h and 8h of OGD time is shown in 
the left panel and GFAP-immunoreactive astrocytes (red) is shown in the 






The primary astrocytic variability was examined in different 2-ketobutyric acid 
concentrations in OGD conditions as shown in Figure 3-29. 0 mM, 1 mM, 2 
mM and 5 mM 2-ketobutyric acid was added to inhibit 3MST expression in 
different extensions. Although after 24h OGD the percentages of the living 
cells were similar (around 40%), the processes in the middle were distinct.  
The cell variability was significantly higher for cells in 2 mM and 5 mM 2-
ketobutyric acid (around 100%) compared to cells in 0 mM and 1 mM 2-
ketobutyric acid (around 70%) in 2 hour time point. Since 2-ketobutyric acid is 
an efficient 3MST inhibitor and 3MST is a H2S-producing enzyme, the results 
indicate that less H2S may protect primary astrocytes from dying in a short 
period of OGD. However at 8 hours the cells in 5 mM 2-ketobutyric acid had 
an even lower cell variability (less than 40%), indicating less H2S may be 





Figure 3-29 Variability of primary astrocytes in different 2-ketobutyric acid 
concentrations in OGD conditions 
Cell variability in different OGD times (0h, 2h, 8h and 24h). 2-ketobutyric acid 
concentrations are 0 mM, 1 mM, 2 mM and 5 mM. The plates were read at 




























3.6. H2S Concentration Determination 
 
3.6.1. Determination of Wavelength for H2S Detection 
 
To demonstrate the efficiency of the probe in the measurement of H2S 
concentration, it was treated with NaHS under a series of different 
concentrations in order to obtain a standard curve of fluorescence intensity 
to wavelength. The concentration of the probe was maintained at 100 μM 
while the concentrations of NaHS varied from 0 to 10 μM as shown in Figure 
3-30, and 50 μM NaHS is shown in Figure 3-31.  
 
Figure 3-30 Fluorescence intensity toward wavelength at different NaHS 
concentrations 
Curve of fluorescence intensity toward wavelength at different NaHS 
concentrations was determined. NaHS concentration: 0, 1, 3, 4, 5, 6, 7, 8, 9, 
10 μM. The wavelength of 482 nm is for excitation and 521 nm is for emission 












































Figure 3-31 Fluorescence intensity toward wavelength at 50μM NaHS 
Curve of fluorescence intensity toward wavelength at 50 μM NaHS was 
determined. The wavelength of 482 nm is for excitation and 521 nm is for 
































3.6.2. H2S Standard Curve  
 
The probe was treated with NaHS under a series of different concentrations in 
order to obtain a standard curve of fluorescence intensity to H2S 
concentration (Figure 3-32). The fluorescence signal in a physiological level of 
H2S is linearly related to the concentration of NaHS (Figure 3-33). These 
results demonstrated that the probe can be utilized to detect H2S both 
qualitatively and quantitatively for latter experiments. The wavelength of 
excitation was 482 nm and emission was 521 nm.  
 
 
Figure 3-32 Curve of fluorescence intensity toward H2S concentrations 
The wavelength of 482 nm is for excitation and 521 nm is for emission to 



















Figure 3-33 Linear correlation of fluorescence intensity toward H2S 
concentration 
The wavelength of 482 nm is for excitation and 521 nm is for emission to 


















3.6.3. H2S Concentration Determination in Primary 
Astrocytes 
 
H2S concentration in primary astrocytes was determined as shown in Table 3-
2. The average absorbance of the four sample is 913.73, so H2S concentration 
is 1.91 μM (95% Cl, 1.73 - 2.09). H2S staining in primary astrocytes was shown 
in Figure 3-34. It is clear that H2S was distributed in both soma and processes 
in astrocytes and the expression was slightly higher near the soma. And the 
result is consistent with 3MST localization. The production of H2S in primary 
astrocytes is probably catalyzed by 3MST.  
 
Table 3-2 Determination of H2S concentration in astrocytes 
H2S concentration in astrocytes was determined. Linear regression is y = 
226.92x + 479.82 (y is absorbance and x is H2S concentration). N=4. 
 Absorbance 
Sample 1 942.241 
Sample 2 904.371 
Sample 3 950.142 
Sample 4 858.166 
Average 913.73 
Standard Deviation 42.085864 





Figure 3-34 Expression and distribution of H2S using fluorescent 
immunohistochemical labelling on primary astrocytes 
Cellular localization of H2S is labeled using fluorescent immunohistochemical 
on primary astrocytes under 20x magnifications. The left panel (green) is the 
staining with H2S and the right panel (green + blue) is the merge of H2S and 
DAPI. All sections were observed with a Nikon fluorescent microscope and 
merged by Nikon's NIS-Elements revolutionizes microscope imaging software. 






4.1. Ischemic Model Selection 
 
The major limitation with the thromboembolic rat model is the degree of 
variability and failure caused by spontaneous recanalization and excessive 
hemorrhage despite of the better pathophysiological relevance. The mortality 
rates are very high in SD rats due to the hemorrhage caused by catheter 
inserted because the inner diameter and length of ICA for every rat is 
different. In that case the reproducibility of this model is heavily dependent 
on the experience of the operator in each individual laboratory. But this class 
of thromboembolic models may still be very useful for experimental stroke 
research in the context of testing antithrombosis and reperfusion therapies. 
There are two major limitations to the suture model. One is the difficulty in 
reproducing consistent infarct volumes. But this can be overcome by 
customizing the size of the suture, the length and diameter of the silicone 
coating, the positioning of the suture insertion and the prevention of the loss 
of the silicone coating. However, the most important criterion for our 
selection was the severity of the model as we required a model which did not 
produce significant recovery within at least 72 hours. In the end we chose the 
permanent transcranial model with a reasonable success rate (70%) and a 
high neurological severity score (14.2 ± 2.6) (Figure 3-13). The model uses a 
permanent cauterization method to induce the systematic interruption of 
regional cerebral blood flow to the left MCA, and it is one of the most 
reproducible models of focal cerebral ischemia in rats. The left MCA cortex 
sustains severe ischemia with reduction in regional cerebral blood flow by 88-
92%. Only very mild ischemia is noted (reduction of blood flow by 10-20%) 
outside the left side. Many studies about post-ischemic edema, angiogenesis, 




4.2. H2S-Producing Enzymes 
 
It has been known that H2S may be synthesized through the actions of 3 
enzymes, CBS, 3MST and cystathionine γ-lyase (CSE).[205, 274] CSE, while 
being important in the cardiovascular system, is considered a minor 
contributor to H2S synthesis in the brain based on its low level of 
expression.[207, 275] CBS can produce H2S either by hydrolyzing its substrate 
Cys or by condensation of Cys and Hcy. Kinetic studies have shown that the 
latter appeared more efficient.[276] On the other hand, 3MST produce H2S 
from 3-MP with pyruvate as the by-product. 3-MP is produced by CAT from 
Cys. Therefore, the two pathways can be commonly regulated by Cys 
availability. However, the regulation of H2S synthesis in the brain is not well 
understood and has been reported to be closely associated with intracellular 
level of Ca2+.[277] Additionally H2S has been found as a mediator of cerebral 
ischemic damage and H2S production increases after stroke.[218] 3MST is 
proved as a major source of H2S production from cysteine and homocysteine 
in the brain, and the activity of 3MST is considerably higher than that of CBS 
in the brain and it may be due to the bound sulfane sulfur which can be 
produced by 3MST efficiently instead of CBS.[278] However, the 3MST 
expression does not increase after acute stroke (Figure 3-15 and Figure 3-19). 
So it implies that another H2S-producing enzyme, CBS, may play a more 
important role after stroke despite a perhaps smaller contribution of H2S 
production under physiological conditions. CSE is an even more unlikely 
possibility as its expression in the brain is still controversial.[210, 279-283]  
 
We have previously reported that H2S level in cortical tissues was increased 
by 2-fold 24h after pMCAO. This increase was not associated with an 
upregulation of CBS expression.[218] Our present observation that 3MST is 
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significantly downregulated under the same conditions would indicate that 
3MST is not likely to be responsible for the increased production of H2S under 
ischemic conditions. This is interesting as CBS and 3MST are supposedly the 
predominant enzymes for H2S synthesis. However, we have now obtained 
preliminary data that show an upregulation of the truncated CBS (45kDa) 
(unpublished) while full-length CBS (62kDa) remained unchanged as reported 
previously. It has been reported that the truncation of CBS was associated 
with increased CBS activities.[284] Most recently, it has been reported that 
NaHS down-regulated both 3MST and CSE in cultured endothelial cells.[285] 
Therefore, it is a distinct possibility that the observed down-regulation of 
3MST is caused by a high level of H2S produced through CBS truncation and 
activation. However, it also needs to pay attention on the importance of 
further characterization of the 3MST antibody. Even though the identity with 
respect to molecular weight is quite convincible, some other methodologies, 
such as antigen preadsorption and immunoblotting in tissues of 3MST 
knockout animals, are still useful to increase the credibility of the present 
results. Additionally, the down-regulation of 3MST after pMCAO is supposed 
to be further confirmed by complementary approaches besides 
immunoblotting and immunohistochemistry, such as 3MST gene expression 
changes after pMCAO. Even though the down-regulation of 3MST gene 
expression does not necessarily mean the consequent protein down-
regulation, it is still very helpful to further validate the present results.  
 
The striking difference between 3MST and CBS is that 3MST produces bound 
sulfane sulfur (a precursor of H2S) that acts as a reservoir of H2S.[205] A 
majority of H2S produced by 3MST is immediately incorporated and stably 
stored as bound sulfane sulfur until released in response to physiologic 
signals which are not well established yet.[237] On the other hand, H2S 
produced by CBS contributes to the labile pool. So it may be argued that 
there is no reason or need for 3MST to be sensitive to the demand of H2S. 
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However, there is currently no evidence that increased release of H2S from 
bound sulfane sulfur occurs in ischemia.    
 
4.3. 3MST Localization 
 
Our finding of astrocytic expression of 3MST contradicts an earlier report that 
3MST is localized to neurons in many areas of the mouse brain and spinal 
cord.[205] In the cortex, 3MST immunoreactivity was reportedly present in 
pyramidal neurons in layers II/III and V, and in layers I-VI of the neocortical 
areas. But according to more reliable double staining instead of 
morphological deduction, the majority of 3MST is expressed in astrocytes 
rather than neurons (Figure 3-6, Figure 3-7 and Figure 3-8).  To rule out the 
possibility of different methodologies, DAB immunohistochemistry against 
3MST was also done in cortex and striatum as shown in Figure 3-9. To rule out 
the possibility of different species, fluorescent immunohistochemistry 
between 3MST and GFAP/NeuN in mouse cortex, striatum, corpus callosum 
and cerebellum was investigated as well, but the same conclusion was drawn 
from the results (Figure 3-10, Figure 3-11 and Figure 3-12). Although 
colocalization with NeuN was not performed in the previous study, the DAB 
immunohistochemical staining presented are convincing. It is difficult to know 
the cause of such discrepancy and any explanation can only be speculative. 
However, an astrocytic localization of 3MST seems consistent with the even 
and unmarkable regional variation of the in vitro 3MST activities. In the 
present study, the main limitation of 3MST localization is the lack of the 
comparison between primary neurons, primary astrocytes and primary 
microglia in terms of 3MST expressions in vitro. The conclusion would be 
more convincible if there were immunoblotting results of cell cultures to 




The regional and temporal expression of CBS was also examined in the CNS 
and it was demonstrated that CBS is preferentially expressed in the radial 
glia/astrocyte. Lineage and the expression is remarkably upregulated in 
reactive astrocytes after KA-induced seizures, and observed histological 
abnormalities in the cerebellum of CBS−/− mice.[215] Nevertheless some 
other publications reported the contrary which claim the predominant 
neuronal immunostaining in cell bodies and neuronal processes of Purkinje 
cells and hippocampal neurons.[217] But later more literature proved that 
CBS is localized to astrocytes,[214] which is an implication that astrocytes are 
the main source of H2S production since 3MST is also localized to them. In 
another point of view, in the developing mouse CNS, neurons are primarily 
generated in the prenatal period, whereas most glial cells are generated from 
the late embryonic to early postnatal period.[286] Therefore, it has been 
suggested that CBS is involved to the generation and differentiation of the 
radial glia/astrocyte lineage cells in the developing CNS. On the other hand, 
compared with the juvenile brain, the CBS protein level was decreased in 
mature brain. The reason for this is unknown currently. However, CBS 
expression was remarkably up-regulated in reactive astrocytes which mediate 
neural recovery in the injured brain after KA-induced seizures, suggesting that 
CBS plays an important role in the maintenance of the mature CNS.[287, 288] 
 
Our results showed that 3MST is localized to astrocytes, and it is previously 
shown that CBS is mainly localized to astrocytes in the brain as well.[214, 215] 
This, therefore, indicates that astrocytes are the major source of H2S in the 
brain, which is consistent with the findings indicating that cultured astrocytes 
synthesized H2S at the rate of about 15 μM/g protein/h, which is 7, 11 and 10 
fold higher than that in microglial cells, NT-2 cells (human neuron-committed 
teratocarcinoma cell line) and SH-SY5Y cells (human neuroblastoma cell line), 
respectively.[216]  H2S has been reported to elicit direct activation of Ca2+ 
influx in astrocytes in response to neuronal excitation. This may be 
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propagated to neighboring astrocytes and hence creating what has been 
termed calcium wave that may modulate nearby synaptic activities.[223] In 
this way, H2S plays a role as neuromodulator although the exact mechanism 
by which H2S causes calcium wave in astrocytes is not clearly understood.[234]  
 
4.4. 3MST and CBS Activity 
 
In the 3MST assay, 2-ketobutyric acid was used as an uncompetitive inhibitor 
of 3MST.[289, 290] This inhibitor attenuated H2S production in all brain 
regions studied by >95%, indicating that the assay measured almost 
exclusively 3MST activity. To the contrary,  H2S production in the CBS assay 
was inhibited by AOAA by only 94 to 48% among the brain regions in the 
order to hippocampus > hypothalamus/thalamus > cortex > striatum > 
midbrain > cerebellum (Figure 3-4). Inhibition was especially low in the 
midbrain and cerebellum (about 50%) (Figure 3-5). This showed that under 
the assay condition, about 50% of the H2S was produced by enzymes other 
than CBS. It is not known which enzyme is involved at present but, as AOAA is 
a remarkable PLP dependent enzyme inhibitor, the enzyme is unlikely to be a 
PLP dependent enzyme.  
 
It has been shown that the activity of 3MST in brain stem and cerebellum is a 
bit higher than that in cortex.[291] We also confirmed that the CBS activity in 
cerebellum is much higher than that in cortex or striatum (Figure 3-4). So the 
H2S produced from cysteine by these two highly expressed enzymes may 
cause cerebellar diseases such as prompt hyperalgesia.[292]  It was previously 
demonstrated that the administration of NaHS causes mibefradil-reversible 
hyperalgesia in rats, implying that H2S might play a pro-nociceptive role in the 
spinal cord as well as in the peripheral tissues.[293-296] On the contrary, the 
inhibition of NaHS-induced hyperalgesia by ZnCl2 is suggestive of some 
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importance of Cav3.2 among T-type Ca2+ channel isoforms, albeit not being 
highly convincing in terms of its specificity. Together with some 
electrophysiological evidence, it appears that spinal and peripheral NaHS/H2S 
may activate or sensitize Cav3.2 T-type Ca2+ channels expressed in the primary 
afferents and/or spinal nociceptive neurons, leading to sensitization of 
nociceptive processing and hyperalgesia.[294, 297] In addition to T-type Ca2+ 
channels, multiple molecular targets for NaHS/H2S have been investigated in 
the CNS and peripheral tissues, including ATP-sensitive K+ (KATP) channels [297, 
298], transient receptor potential (TRP) A1 channels [299], nitric oxide [300, 
301] or nitric oxide synthase [302, 303], and others [304, 305]. These might 
directly or indirectly affect functions of nociceptors or nociceptive processing. 
Either activation of KATP channels by NaHS suppress nociception or 
pretreatment with glibenclamide, an inhibitor of KATP channels, did not 
modify NaHS-elicited hyperalgesia in rats.[294] Also there is conflicting 
evidence for the roles of TRPV1 channels in activation of the primary 
afferents by NaHS since TRPV1 antagonists inhibit neurally mediated effects 
of NaHS in some studies, but not in the others [294, 306-308] while 
electrophysiological evidence for direct stimulation of TRPV1 channels by 
NaHS/H2S is lacking. Hence while NaHS/H2S might not directly target TRPV1, 
TRPV1 could indirectly contribute to the effect of NaHS/H2S. This may give us 
a potential solution about diseases caused by H2S over production in 
cerebellum.  
 
4.5. Roles of Astrocytes 
 
Under most circumstance, astrocytes protects neurons via variable 
approaches, including regulation of ionic homeostasis and membrane 
potentials in both astrocytes and neurons, control of extracellular glutamate 
levels, and expansion of the glycolytic capacity during ischemic damage[309], 
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but under certain conditions, activated astrocytes contribute to the ischemic 
cell death.[310] And one of the mechanisms by which activated astrocytes kill 
neurons is high level of glutamate.[311, 312] As we know that glutamate and 
3MP can be converted from cysteine and α-ketoglutarate at the present of 
CAT, and 3MP is a substrate of H2S production [313, 314] In cocultures, 
activation of astrocytes or microglia produces NO, which  decreases ATP levels 
in the cocultured neurons and stimulates glutamate release and lactate 
production. So indirectly the NO produced by activated astrocytes and 
microglia cause rapid (<1 min) release of glutamate in neuronal-astrocytic 
cultures leading to subsequent neuronal death.[315] So it may be an 
explanation that why the inflammatory neurodegeneration is induced by 
activated astrocytes when there is an excessive release of glutamate. It is also 
illustrated in a rat pMCAO model applying hyperbaric oxygen treatment, 
suppression of microgliosis and aggravated response of astrocytes induced by 
pharmaceutical agents or therapies might improve postischemic 
outcome.[316] And many other animal experiments also proved some of the 
glutamate-mediated neuronal damage can be attenuated by administration 
of antagonists of glutamatergic receptors.[317, 318] Also, if extracellular 
glutamate level is reduced in peri-infarct area, the infarct expansion after 
middle cerebral artery occlusion can be inhibited to a certain extent.[319-321]  
 
4.6. H2S Probe 
 
The current methods for the detection of H2S, such as colorimetric assays, gas 
chromatography, and polarography analysis, require the homogenization and 
extraction from cells and tissues. Several factors can influence the accuracy of 
assays that purport to measure the H2S concentration. First, H2S rapidly 
diffuses from the biopsied tissue sample into the atmosphere, so it has to be 
measured in a remarkably short time. Second, tissues have the capability of 
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enzymatically producing and catabolizing endogenous H2S [209, 322, 323], 
with the balance between these two reactions determining the tissue 
concentration of free H2S. Alteration of this balance during the analytical 
technique influences the accuracy of the estimation of the H2S concentration 
that existed in vivo. Last, H2S tends to rapidly react with glass and metal; thus, 
the procedures associated with those kinds of equipment such as typical 
homogenization will affect the accuracy of H2S determination. Recently we 
collaborated with a group who invented a fluorescent probe to detect H2S 
specifically and in real-time as described in materials and methods.[236] This 
probe proved to be selective for H2S and it did not proceed with other 
biological thiols such as cysteine and glutathione. Using this probe and the 
customized method, H2S level in primary astrocytes was determined as 1.91 
μM (95% Cl, 1.73 - 2.09) (Table 3-2). It was reported that H2S endogenous 
level is 0.12 μmol/kg tissue (95% Cl 0.06 - 0.18) in the whole brain. However, 
the concentration was measured in the homogenized brain tissue. 
Considering the density of the rat brain tissue is 1.054 g/cm3 [324], the 
concentration of H2S in primary astrocytes is still about 15 fold higher than 
what was previously reported in the whole brain. This is entirely consistent 
with the idea that H2S is primarily produced in astrocytes. It has been 
reported that the rate of H2S synthesis in astrocytes is about 7 fold higher 
than in microglial cells and 10 fold higher than in neuronal cells.[216] In 
addition, the previously reported data were obtained in vitro after tissue 
processing and time delay. That would also result in underestimation. 
However, the accuracy of the estimation of H2S concentration in primary cells 
is probably compromised by an in-vitro assay standard curve with an R2 of 
0.92. Besides of the technological nonproficiency, it was probably also due to 
the hard decision on incubation time with the balance between the rapid 




Endogenous levels of sulfide have been measured in the brains of rats, 
bovines and humans [229, 325, 326], but relatively high concentrations of 
hydrochloric acid or trichloroacetic acid were generally used to release H2S in 
these studies. Therefore, the amounts measured were not free H2S actually, 
but H2S released from acid-labile sulfur. Some study showed that the critical 
pH to release H2S from acid-labile sulfur is 5.4.[208]  Acid-labile sulfur, which 
mostly consists of iron-sulfur complex of enzymes involved in oxidative 
phosphorylation, is localized mainly to mitochondria.[327, 328] Because 
mitochondria usually do not become acidic, it may be hard for H2S to be 
released from acid-labile sulfur under physiologic conditions. So one of the 
advantages of the probe is the easy differentiation of H2S from the bound 
forms of this compound. In the present study, the traditional colorimetric 
assay was also utilized for the detection of H2S, but we used the method to 
measure CBS and 3MST activities instead of endogenous H2S level as 
substrates were provided and strong acid was added. However the probe was 
used to measure H2S in the primary astrocytes where both H2S and acid-labile 
H2S remained intact. An important potential of the probe is to detect H2S 
concentrations in real-time in view of the extremely short half-life of H2S.[228, 
329] The main limitation of the probe is the confirmation of specificity. Even 
though our collaborator has already ruled out the possibility of the 
fluorescent excitation by other biological nucleophiles, especially thiols such 
as cysteine and glutathione, the validation of the fluorescent H2S probe is still 
necessary. The appropriate inhibitors or activators should also be utilized for 
further confirmation of the specificity. For CBS, AOAA and HA can be used as 
the inhibitors even though they are criticized as nonspeciﬁc inhibitors of a 
number of PLP-dependent enzymes.[73, 74] SAM can be used as CBS 
activator for its efficiency and less systemic toxicity.[240] For 3MST, 2-
ketobutyric acid and thioredoxin are generally used as the inhibitor and 
activator, respectively.[76, 78] However, it should be noticed that during the 
experiment, the fluorescent pictures need to be taken without the original 
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incubation medium to diminish the background, while there are also 
inhibitors and activators existing in the medium, and the inhibition or 
activation quite relies on a continuous and consistent concentration in the 
incubated medium. So a considerably rapid picture taking process is probably 




Besides the shortcomings covered previously, there are still several limitations 
as listed below:  
 Even though the normal rat brain was dissected into six regions for the 
determination of 3MST regional activities, the investigation of 3MST 
expression after pMCAO was only in cortex, striatum and corpus 
callosum. The main reason is the major infarct area of pMCAO is 
located in these three regions. However some recent study also 
showed the secondary injury of separated infarction in cerebellar 
cortex after middle cerebral artery occlusion in rats.[77] So a thorough 
investigation of 3MST in the whole brain before and after pMCAO is 
probably necessary.  
 The pMCAO model is not the most sophisticated one, but the 
reproducibility is still largely dependent on the experience of the 
operator and surgical nuances each time. Sometimes the variability 
and excessive failure was caused by poor feeding due to the 
destruction of muscles and joint needed for chewing. The possible 
solution to the problem is reducing the invasion on the muscles and 
bones as much as possible and less touching the nerves when the 
model is conducted.  
 Anesthetic agents sometimes have a profound effect on the 
pathophysiology of cerebral ischemia. In this present study, ketamine-
xylazine was used. However some study showed that ketamine 
interacts with µ, κ, and δ opioid receptors, and at high doses, 
ketamine even blocks sodium channels.[95] And several studies have 
also shown that ketamine produces neurotoxicity. In rat and monkey 
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cortical cultures, 10 µM ketamine increased DNA fragmentation but 
not release of lactate dehydrogenase (a well-established marker for 
necrotic cell death), suggesting that ketamine caused neuronal death 
specifically through apoptosis.[96, 97] A possible solution is to replace 
ketamine-xylazine by a more reliable anesthetic agent such as 
Isoflurane, whose anesthetic effect is mediated by antagonizing the N-
methyl D-aspartate receptor, although the neuroprotective effect was 
also found in samples after ischemic injury.[84, 86] 
 In the investigation of 3MST expression after pMCAO, western blot 
and immunohistochemistry were both used. However, the control for 
western blot result was contralateral brain tissue while the control for 
immunohistochemistry was sham-operated animals. The reason is 
that western blot experiment costs more animals. So for the less 
consumption of animals, 3MST expression of contralateral side was 
used as the control for western blot results. This could be easily 
addressed by increasing the number of animals, if some studies 
conclude the imparity between contralateral cerebrum, sham-
operated cerebrum and normal cerebrum.  
 The 3MST down-regulation was concluded in both cortex and striatum, 
and confirmed by immunohistochemistry. Also it was found that there 
is no change in terms of 3MST expression in corpus callosum, but no 
western blot was used to validate the finding. The reason is that 
corpus callosum is relatively thin and remarkably difficult to dissect 
after pMCAO. The possible solution to double confirm the finding is by 
electromagnetic methodology such as computed tomography.  
 We chose five time points for 3MST expression after pMCAO for 
western blot experiment, which are 0h, 3h, 8h, 24h and 72h. However 
there are just three time points for immunohistochemistry experiment, 
which are 0h, 24h and 72h. The reason is that it is very hard to 
distinguish any difference with respect to 3MST activities visually in a 
short time point in immunohistochemistry, and the identity between 
ipsilateral and contralateral tissue in 3MST activities was also 
observed by western blot results. However we might also miss some 
slight changes during a short time of ischemia.  
 There is no double staining for 3MST expressions in cerebellum and 
midbrain for the lack of relative cell markers. We tried anti-
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parvalbumin as granule marker and anti-Calbindin-D-28K as purkinje 
marker. However, no positive staining was found in both DAB 
immunohistochemistry and fluorescent immunohistochemistry. It was 
unlikely to be the technical problems since positive double staining 
had already been produced in three cell types in cerebrum. The 
address of the problem probably relies on more specific antibodies of 
the cell markers in cerebellum.   
 The H2S probe was not used in tissue in the present study. The reason 
is the probe can hardly penetrate into the tissue despite the 
surfactant we use, CTAB. Currently the group is developing an NIR 




CHAPTER 2: Vasculome Mapping for 




Mild traumatic brain injury may be induced by biomechanical forces 
transmitted directly or indirectly to the brain.[330-332] While there is no 
universal agreement on the definition of “mild traumatic brain injury”, there 
may or may not be loss of consciousness, although a concussion typically 
does involve some period of transient amnesia which tends to be anterograde 
and does not involve a loss of autobiographical information.[331] However, 
some degree of retrograde amnesia often occurs initially but tends to resolve, 
usually within hours in most patients, while a period of the post-traumatic 
amnesia is often permanent.[333] Although gross structural abnormalities on 
standard CT scan and MRI are typically absent in concussion,[332, 334] at a 




Most cases of traumatic brain injury are concussions. A World Health 
Organization (WHO) study estimated that between 70 and 90% of head 
injuries that receive treatment are mild,[336] but in the sporting arena the 
underreport rate is relatively high.[337-339] So it is difficult to estimate the 
frequency of mild traumatic brain injury due to underreporting and to the 
widely varying definitions of concussion and mild traumatic brain.[340] At 
least 25% of mild traumatic brain injury sufferers fail to get assessed by a 
medical professional.[341] The WHO group reviewed studies on the 
epidemiology and found a hospital treatment rate of one to three per one 
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thousand people, and they estimated that the rate per year in the general 
population is over six per one thousand people since not all concussions are 
treated in hospitals. The reasons for its underreporting include players’ lack of 
awareness of the symptoms or significance of concussion, their personal 
desire and outside pressure to continue playing, and the perception that 
reporting concussion could have adverse professional and financial 
consequences for the player and the team.[337, 339] As expected, contact 
sports such as American football, rugby, soccer, boxing, wrestling, basketball, 
field hockey and lacrosse are all associated with a relatively high prevalence 
of concussion.[338, 342] International studies of the rate of concussion 
among professional, non-professional, and school-level rugby players suggest 




The recognition, assessment, and classification of concussion can be 
challenging. Certainly, concussions that lead to dramatic findings, such as 
prolonged loss of consciousness, will be readily detected. However, the most 
of concussions result in more subtle findings.[344-352] Furthermore, loss of 
consciousness is not a consistent predictor of cerebral dysfunction or length 
of recovery.[346, 348, 353] The most common symptoms of concussion are 
headache and dizziness.[347, 350, 354-357] It should be noted that although 
all of these sorts of symptoms can be seen with concussion, not every athlete 
experiencing these symptoms has a concussion. Indeed, many of these 
symptoms can be due to other etiologies.[358] Given the nonspecific 
symptoms and lack of self-reporting, the diagnosis can be very hard to 
make.[337, 354, 359] The on-field assessment of an acute sport-related 
concussion, similar to all medical assessments, is obliged to begin with the 




1.3. Risk Factors 
 
As mentioned in the Consensus Statement on Concussion in Sport, 
concussion may be caused by a direct impact to the head, or by an impact to 
another part of the body with an impulsive force indirectly transmitted to the 
head.[332] While falls and motor vehicle accidents are the most common 
causes in grown-ups, contact sports and bicycle accidents account for the 
majority of concussions in children and adolescents.[331] A distinguishing 
feature of sports-related concussion compared to non-sports-related 
concussion, such as from motor vehicle or cycling accidents, is that it often 
results from lower speed impacts. As such, sports-related concussion is more 
often associated with disorientation or a relative impairment of conscious 
state instead of loss of consciousness.[339, 363, 364] Risk factors for sports 
concussion include organized sports as opposed to leisure exercises, actual 
games rather than practice sessions, and the subgroup of high-school athletes 




In both animals and humans, mild traumatic brain injury can change brain 
physiology from hours to weeks, setting into motion a variety of pathological 
events.[365] Though these events are thought to interfere with neuronal and 
brain function, the metabolic processes after concussion are reversible in a 
large majority of affected brain cells while a few cells may die after the 
injury.[341] From a biomechanical perspective, concussion is thought to be 
due to rotational or angular acceleration forces applied to the brain causing 
neuronal shearing instead of the linear acceleration-deceleration forces that 
frequently produce focal macroscopic brain damage.[339, 366-368] Brief loss 
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of consciousness associated with concussion seems to be due to rotational 
forces centered on the midbrain and thalamus that cause the transient 
disruption of components of the reticular activating system.[331]  
 
The ultrastructural basis of concussion is associated with the immediate 
stretching of axons and increased permeability and disruption of neuronal 
membranes, as part of diffuse axonal injury (DAI).[335, 369, 370] 
Biochemically there is an abrupt and indiscriminate release of 
neurotransmitters, especially for the excitatory neurotransmitter 
glutamate.[371] The ensuing abnormal ion fluxes lead to excessive 
accumulation of extracellular K+ and intracellular Ca2+, which leads to a 
massive neuronal excitation and depolarization, accompanied by a period of 
compensatory homeostatic ion pump-driven glucose catabolism to generate 
more of the cellular energy currency, adenosine triphosphate (ATP). The 
excitatory phase that may be involved to seizure activity is followed by a wave 
of neuronal suppression referred to as spreading depression.[372, 373] 
Persisting cognitive deficits after a concussive injury may also be elevated 
from dysfunctional neurotransmission in one or more of the glutamatergic, 
adrenergic and cholinergic systems.  
 




All experiments were performed following an institutionally approved 
protocol in accordance with the National Institute of Health's Guide and 
Institutional Animal Care and Use Committee. For the entire study, male CD-1 




2.2. Closed Head Injury Model 
 
Mild traumatic brain injury was induced by means of the closed head injury 
model. Mice were anesthetized with 4% isoflurane (Anaquest, Memphis, TN) 
in 70% N2O and 30% O2 using a Fluotec 3 vaporizer (Colonial Medical, 
Amherst, NH) and positioned in a stereotaxic frame. Anesthesia was 
maintained using 2-3% isoflurane while the scalp was incised to expose the 
skull. A pneumatic cylinder was used to deliver a single impact to the skull 
surface of left parietal bone. Mice were subjected to closed head injury using 
a pneumatic cylinder with a 2-mm flat-tip impounder, velocity 5.1 m/sec, 
depth of 0.2 mm or 0.4 mm, and 100 msec impact duration. Mice with 
depressed skull fractures were excluded. The scalp was then closed and the 





2.3. Behavioral Tests 
 
2.3.1. Neurological Severity Score 
 
A 10-point neurological severity score (NSS) was used for assessment of 
posttraumatic neurological impairment. A brief description of the NSS is 
presented in Table 2-1. The score consists of 10 individual clinical parameters, 
including tasks on motor function, alertness, and physiological behavior, 
whereby 1 point is given for failure of the task and no point for succeeding. A 
maximal NSS of 10 points indicates severe neurological dysfunction, with 
failure at all tasks. In the present study, the NSS was assessed at t = 0 hour, 3 
hours, 1 day, 3 days and 7 days after trauma. Evaluation of task performance 
was performed by two investigators who were blinded about the animal 
groups. The total NSS, calculated as the difference between the NSS at t = 0 
hour and the NSS at any later time point, is a parameter that reflects the 





Table 2-1 Mouse NSS for assessment for neurological impairment 
    Points 
Task Description Success/Failure 
Exit circle Ability and initiative to exit a 
circle of 30 cm diameter (time 
limit: 3 minutes) 
0 1 
Mono-/Hemiparesis Paresis of upper and/or lower 
limb of the contralateral side 
0 1 
Straight walk Alertness, initiative, and motor 
ability to walk straight, once the 
mouse is put on the floor 
0 1 
Startle reflex Innate reflex; the mouse will 
bounce in response to a loud 
hand clap 
0 1 
Seeking behavior Physiological behavior as a sign of 
“interest” in the environment 
0 1 
Beam balancing Ability to balance on a beam of 7 
mm width for at least 10 seconds 
0 1 
Round stick balancing Ability to balance on a round stick 
of 5 mm diameter for at least 10 
seconds 
0 1 
Beam walk: 3 cm Ability to cross a 30 cm long 
beam of 3 cm width 
0 1 
Beam walk: 2 cm Same task, increased difficulty on 
a 2 cm wide beam 
0 1 
Beam walk: 1 cm Idem, increased difficulty on a 1 
cm wide beam 
0 1 





2.3.2. Wire Grip Test 
 
Vestibulomotor function was assessed using a wire-grip test as presented in 
Table 2-2.[374] Mice were placed on a steel wire (45 cm long) suspended 45 
cm above protective padding and were allowed to traverse the wire for 60 
seconds. The latency that a mouse remained on the wire within a 60 seconds 
interval was measured, and a wire grip score was quantitated using a 5-point 
scale. Testing was performed in triplicate and an average value calculated for 
each mouse at t = 0 hour, 3 hours, 1 day, 3 days and 7 days after trauma. 
 
Table 2-2 Mouse wire grip score  
Task Points 
Less than four limbs griping the wire and inability to stay on the wire 
for 30 seconds 
0 
Less than four limbs griping the wire and ability to stay on the wire 
for more than 30 seconds 
1 
Four limbs griping the wire for more than 5 seconds 2 
Four limbs griping the wire and moving further than a body length 3 
Four limbs griping the wire and moving to the end of the wire 4 







2.3.3. Corner Test 
 
Each mouse was placed between two boards each with dimension of 30 × 20 
× 1 cm. The edges of the two boards were attached at a 30° angle with a small 
opening along the joint between the two boards to encourage entry into the 
corner. The mouse was placed between the two angled boards facing the 
corner and half way to the corner. When entering deep into the corner both 
sides of the vibrissae are stimulated together. The mouse then rears forward 
and upward, then turns back to face the open end. The non-traumatic mouse 
turns either left or right, but the traumatic mouse preferentially turns toward 
the non-impaired side. The turns in one versus the other direction were 
recorded from ten trials for each test. Turning movements that were not part 
of a rearing movement were not scored. The corner test was performed at t = 
0 hour, 3 hours, 1 day, 3 days and 7 days after trauma. 
 
2.3.4. Foot Fault Test 
 
Mice were tested for placement dysfunctions of forelimbs with the modified 
foot fault test.[375] A mouse was placed on an epoxy-coated wire grate (bars 
2.5 mm in diameter, spaced 1 cm apart) and videotaped for 30 seconds from 
below the grate. Each successful foot placement was recorded as a step. A 
paw slipping through the grate was considered a foot fault. The number of 
faults were determined within the 30 seconds. The foot fault evaluation was 
performed at t = 0 hour, 3 hours, 1 day, 3 days and 7 days after surgery. 
 
2.3.5. Y-Maze Test 
 
This test was based on the innate preference of mice to alternate arms when 
exploring a new environment. Mice were placed in a Y-shaped maze for 8 min 
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and the number of arms entered, as well as the sequence of entries, was 
recorded and a score was calculated to determine alternation rate (degree of 
arm entries without repetitions). A high alternation rate is indicative of 
sustained cognition as the animals must remember which arm was entered 








3.1. Motor Assessment 
 
There was no difference between 0.2 mm depth trauma and 0.4 mm depth 
trauma in terms of body weight which grew in a normal rate for both groups 
(Figure 3-1). Similarly there was no difference with respect to neurological 
severity score (Figure 3-2). At 3h neurological severity score seemed to 
increase a bit but it was not significant and returned to 0 rapidly (Figure 3-2).  
For wire grip score, at 3h the scores for both groups were significantly 
different with 0h and they were distinct between the two groups, indicating 
that there might be slight changes in terms of motor ability after 3h (Figure 3-
3). Corner test and foot fault test were resemble to neurological severity 
score. A slight elevation at 3h was followed by rapid drop down to normal 





Figure 3-1 Mouse body weight after mild traumatic brain injury 
Mouse body weight was scaled at 0 hour, 3 hours, 1 day, 3 days and 7 days 
after mild traumatic brain injury. The 0.2 mm impact depth is marked by 




























Figure 3-2 Mouse NSS after mild traumatic brain injury 
Neurological severity score (NSS) was measured at 0 hour, 3 hours, 1 day, 3 
days and 7 days after mild traumatic brain injury. The 0.2 mm impact depth is 






















Figure 3-3 Mouse wire grip score after mild traumatic brain injury 
Wire grip score was measured at 0 hour, 3 hours, 1 day, 3 days and 7 days 
after mild traumatic brain injury. The 0.2 mm impact depth is marked by 





























Figure 3-4 Mouse corner test after mild traumatic brain injury 
The number of left turn was measured in ten time total turn at 0 hour, 3 
hours, 1 day, 3 days and 7 days after mild traumatic brain injury. The 0.2 mm 
impact depth is marked by dashed line and 0.4 mm impact depth is marked 


























Figure 3-5 Mouse foot fault test after mild traumatic brain injury 
Steps of fault was measured within 30 seconds at 0 hour, 3 hours, 1 day, 3 
days and 7 days after mild traumatic brain injury. The 0.2 mm impact depth is 


























3.2. Cognitive Assessment 
 
In the Y-maze experiment, mild traumatic brain injury group and sham group 
were tested in terms of spontaneous alternation in Y-maze and number of 
arm entries. And no differences were found between the two groups. The 
percentage of spontaneous alternation was between 60% and 70% while the 






Figure 3-6 Mouse Y-maze test after mild traumatic brain injury 
Y-maze test was done at 4 days, 7 days and 14 days after mild traumatic brain 
injury. The mild traumatic brain injury is marked by full line and sham group is 




















































Controlled traumatic brain injury employing a pneumatic impactor was first 
introduced for use in laboratory ferrets by Lighthall and colleagues and 
subsequently adapted for rat in an attempt to better control the 
biomechanical parameters of brain injury.[376-378] Dissimilar to the fluid 
percussion injury device that disperses a stream of solution intracranially that 
cannot be readily quantified, the controlled cortical impact model of 
experimental brain injury takes advantage of biomechanical events 
contributing to injury. These biomechanical events can be analyzed by 
establishing a quantifiable relationship between measurable engineering 
parameters such as force, velocity, and tissue deformation, and the 
magnitude of tissue insults and functional impairment. These controlled 
mechanical variables enable accurate, calculable, and independent control of 
the deformation parameters over a wide range of contact velocities. 
 
While this model produces a range of neurological deficits that are alike to 
those produced by fluid percussion, the deficits are achieved with much less 
mortality and apnea. The high injury level, with a mortality rate of 17%, 
produced neurologic deficits comparable to fluid percussion injury which has 
reported mortality rates of about 40%.[379, 380] One explanation may be 
that cortical impact produces less brain-stem mediated pathophysiology than 
fluid percussion.  
 
There are also comparisons between cortical impact injuries produced by 
controlled traumatic brain injury and those produced by weight drop method. 
Biomechanically, the pneumatic impactor allows greater control in terms of 
the velocity and duration of the impact. While the impact velocities of weight 
drop techniques do not exceed 2 m/s, our pneumatically driven impactor can 
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manage the velocity of 5.1 m/s. Neurologically, both techniques can similarly 
produce enduring neurological deficits. Histopathologically, both techniques 
at moderate to high injury severities produce a necrotic cavitation in the 
white matter in the injury site.[381] However, unlike the weight drop 
technique, at high injury levels the pneumatic technique can produce gross 
histopathologic alterations distant from the injury site at high injury severities. 
These distal injuries may be attributable to the greater impact velocities that 
are associated with.  
 
For the model establish of mild traumatic brain injury, an ideal mild model is a 
brain trauma resulting in short time deficits and rapid recovery after the 
insults. In this project, at 3h neurological severity score increased a bit and 
returned to 0 rapidly (Figure 3-2).  For wire grip score, at 3h the scores for 
both groups were significantly different with 0h and they were distinct 
between the two groups, indicating that there are slight changes in terms of 
motor ability after 3h (Figure 3-3). Corner test and foot fault test were 
resembled to neurological severity score. A slight elevation at 3h was 
followed by rapid drop down to normal (Figure 3-4 and Figure 3-5). These 
behavioral data give a clear evidence that it is an ideal mild traumatic brain 
injury model for the genetic investigation, but the relative western blot or 
microarray results applying the model in the future are also important test 
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